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ABSTRACT 
Human norovirus (HuNoV) is the causative agent of the winter vomiting disease and 
the leading cause of outbreaks of gastrointestinal infections across all settings and 
age groups in the world. The virus is highly contagious making outbreaks difficult or 
often impossible to control and having a high impact on societal costs and resources. 
Therefore, there is a high urge for the design and development of a HuNoV vaccine. 
Since research on HuNoV biology and pathogenesis has been hampered by the 
inability to infect and efficiently propagate the virus in cell cultures, HuNoV receptor 
studies that address antibody-mediated protection against HuNoV have not been 
possible. However, such a model has recently been developed. This thesis has 
focused on two crucial steps towards the development of a novel mucosal 
subcomponent HuNoV vaccine. The first was to identify membrane components 
carrying histo-blood group antigens (HBGAs) that are required for HuNoV infection 
in the epithelial cells of the human intestine, represented as cultures of human 
intestinal enteroids (HIEs). The second step was to identify highly immunogenic 
peptides from the HuNoV capsid for generating a subcomponent vaccine that 
stimulates strong and long-lasting HuNoV-specific immune responses. The key 
findings have advanced our basic knowledge on the lipid, glycolipid and 
glycoprotein composition of HIEs, established from jejunal biopsies of individuals 
with different ABO, secretor and Lewis status. These components may all be of 
importance for understanding the pathogenesis of HuNoV gastrointestinal infection, 
as well as contribute in designing a mucosal subcomponent vaccine against HuNoV 
effectively preventing future HuNoV disease and outbreaks. 
Keywords: human norovirus; gastrointestinal infection; mucosal vaccine; 
subcomponent vaccine; human intestinal enteroids; histo-blood group antigens; 
lipidomics; glycoproteomics; glycosphingolipids. 
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SAMMANFATTNING PÅ SVENSKA 
Humant norovirus (HuNoV) är orsaken till vinterkräksjukan och den största 
anledningen till utbrott av gastrointestinala infektioner i alla typer av miljöer 
och bland alla åldersgrupper i världen. Viruset är oerhört smittosamt vilket 
gör att utbrott är svåra eller ofta omöjliga att kontrollera och har stor 
påverkan på samhälleliga kostnader och resurser. Det finns därför ett stort 
behov av att ta fram och utveckla ett vaccin mot HuNoV. Forskningen kring 
biologin och patogenesen hos HuNoV har hämmats av vår tidigare oförmåga 
att infektera och på ett effektivt sätt föröka viruset i cellkulturer. Därför har 
identifiering av receptorerna för HuNoV liksom utveckling av ett fullgott 
antikroppsmedierat skydd inte tidigare varit möjligt. Dock har en sådan 
experimentell modell nyligen utvecklats. Den här avhandlingen fokuserar på 
två avgörande steg mot utvecklandet av ett unikt per oralt 
delkomponentvaccin mot HuNoV. Det första steget var att identifiera 
membrankomponenter som bär på vävnads-blodgrupps antigener (HBGAs) 
som behövs för infektion av HuNoV i epiteliala celler i människans tarm, 
representerade av in vitro kulturer av humana minitarmar s.k. enteroider 
(HIE:s). Det andra steget var att identifiera starkt immunogena peptider från 
HuNoV’s kapsel för att framställa ett delkomponentsvaccin som stimulerar 
till ett starkt och långvarigt HuNoV-specifikt immunsvar. 
Nyckelupptäckterna har fördjupat våra baskunskaper om lipiders, 
glykolipiders och glykoproteiners sammansättning i HIEs, etablerade från 
tunntarms biposier från individer med olika ABO, sekretor och Lewis status. 
De här komponenterna är av stor betydelse för förståelsen av patogenesen av 
gastrointestinala infektioner orsakade av HuNoV och kommer 
förhoppningsvis bidraga till att designa ett peroralt komponentvaccin mot 
HuNoV som effektivt förhindrar framtida HuNoV-infektioner och 
sjukdomsutbrott. 
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1 
1 NOROVIRUS
 
1.1 HISTORY 
Gastrointestinal infections or gastroenteritis of nonbacterial etiology have 
been studied widely between 1950 and 1960 during the “golden age” of 
virology. However, attempts to identify an agent causing an infection 
resembling of “winter vomiting disease” first described by Zahorsky in 1929 
(1) were unsuccessful even with the help of latest tissue-culture techniques. 
As researchers learnt later, it wasn’t the first challenge by norovirus (NoV) to 
scientific community.  
The emphasis on defining a viral etiologic agent of acute gastroenteritis was 
raised 40-50 years ago. It was based on several observations. Most of 
infectious gastroenteritis occurring among young children and adults did not 
have any identified etiology (2, 3). Since bacteria were rarely found as 
causative agents, it was assumed that the main cause should be of viral origin 
(2, 3). Furthermore, gastroenteritis could be induced in adult volunteers using 
bacteria-free stool filtrates derived from naturally occurring gastroenteritis 
outbreaks (4). Using latest techniques, as organ cultures, was promising as an 
easier way of identification of nonbacterial etiology agents. Though available 
organ cultures helped to discover such viruses such as the ECHO and 
coxsackie (2, 3), the cause of “winter vomiting disease” remained 
unidentified. Thus, there was a need to look for other techniques to resolve 
the viral etiology of this disease.  
The breakthrough came in October 1968 with another outbreak of acute 
gastroenteritis in an elementary school in Norwalk, Ohio.  Symptoms were 
mostly vomiting and nausea with some developing diarrhea (5). 
Unfortunately, classical laboratory studies and cell or organ cultures did not 
reveal an etiological agent. However, stool filtrates from the outbreak were 
used for volunteer studies to prove their infectiosity and to collect 
convalescent serum from challenged volunteers (6). In 1972 Dr. Albert 
Kapikian made the first attempt to combine the low titer, but infectious, stool 
filtrate from the Norwalk outbreak with immune serum from volunteers and 
could visualize the virus using electron microscopy (the method was called 
immune electron microscopy). Finally, clear aggregates of non-enveloped 
and antibody-coated virus-like particles of only 27 nm size were visualized 
(Fig. 1)(6). These virus particles were confirmed to be the cause of the 
Gastrointestinal norovirus infections and the development of the next generation of mucosal vaccines 
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Norwalk gastrointestinal infection outbreak and so the name “Norwalk virus” 
was given to the etiological agent of winter vomiting disease.  It was finally 
settled as NoV by an international committee on taxonomy of viruses in 2002 
(ICTVdB2004). 
 
 
 
 
 
 
Figure 1. A virus aggregate observed after incubation of stool filtrate with convalescent 
serum using electron microscopy. It was identified as the cause of the “winter vomiting 
disease” outbreak in Norwalk and referred to as Norwalk virus. (6) 
1.2 CLASSIFICATION 
Noroviruses belong to the Caliciviridae family, which also comprises four 
other genera: Sapovirus, Lagovirus, Vesivirus and Nebovirus. All genera have 
closely related genome structures, but are genetically and antigenically 
distinct. They also infect different species. Sapovirus infects porcine, mink, 
dogs, sea lions, bats and humans. They are the second most common cause of 
human gastroenteritis after norovirus within thr Caliciviridae family. 
Lagoviruses are well known for causing hemorrhagic disease in lagomorphs, 
like rabbits and hare. Vesiviruses have feline calicivirus as the major 
representative of the genus and neboviruses are infectious to cattle.  
Noroviruses are genetically classified into 10 genogroups (GI to GX) or 
could also be divided into 60 P-types (14 GI, 37 GII, 2 GIII, 1 GIV, 2 GV, 2 
GVI, 1 GVII and 1 GX) based on their nucleotide diversity of the RNA-
dependent RNA polymerase (7). GI, GII, GIV, GVIII and GIX (re-classified 
GII.15) viruses can infect humans, where GI and GII are responsible for the 
majority of gastrointestinal infections caused by noroviruses. GIII viruses 
infect cows and sheep, GIV.2 can infect dogs and cats, GV – mice and rats, 
GVI and GVII – dogs, and GX – bats. Two more new genogroups are in the 
process of being assigned, GNA1 (found in harbor porpoise) and GNA2 
(found in sea lions). Genogroups are further divided into genotypes based on 
phylogenetic clustering of the complete VP1 capsid protein amino acid 
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sequence.  There are nine genotypes in the GI group, where GI.1 is the 
Norwalk virus. The group causes one tenth of all NoV outbreaks (8). 
Genogroup GIV comprises only two genotypes with GIV.1 being the only 
one infecting humans, and GIV.NA1 to be confirmed. Epidemics caused by 
GIV.1 are rarely detected. The GII genogroup is the largest and has 26 
genotypes along with two tentative genotypes, GII.NA1 and GII.NA2. 
Genotypes GII.11, GII.18 and GII.19 are specific to porcine only. Though 
genetic diversity among noroviruses is wide, a single genotype appears to 
cause the majority of norovirus outbreaks around the world. Specifically, 
GII.4 genotype has learnt to evolve genetically giving rise to new strains 
every 2-3 years and replacing previous strains. GII.4 genotype is responsible 
for around 80% of all outbreaks caused by human norovirus (9). The global 
GII.4 strains to mention include the US95/96 (emerged in 1995), Farmington 
Hills (2002), Hunter (2004), Den Haag (2006), New Orleans (2009) and 
Sydney (2012). Many other strains of GII.4, e.g. GII.4 Dijon171/96 (1996) or 
GII.4 Ast6139 (2000), which were also used in our studies, might not have 
spread globally, but were identified as unique and named after the location 
where cases occurred sporadically (10).  Lately, emergence of rare genotypes 
(GII.17 (11, 12)) and new recombinant genotypes (GII.P16-GII.4 and 
GII.P16-GII.2 (13)) causing outbreaks and sporadic cases (14) suggests that 
evolution of NoV is not complete and the classification might be extended in 
the future.  
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Figure 2. The diversity of norovirus genus (A) and GII genogroup (B). Genogroups or 
genotypes in red have been designated recently (7). 
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1.3 STRUCTURE 
Norovirus is a positive-sense single stranded RNA virus. Its’ genome length 
is 7.7 kb and it is organized into 3 open reading frames (ORFs) (Fig. 3a). 
ORF1 encodes a non-structural polyprotein, which is processed post-
translationally by the viral 3C-like protease (3CLpro) into at least 6 proteins 
(15).  The identified proteins begin from N terminal in the following order: 
p48, which has been associated with cellular trafficking (16); NTPase, the 
nucleoside triphosphatase; p22, which been related to Golgi disruption and 
inhibition of protein secretion (17); VPg, viral genome-linked protein, which 
is proposed to interact with translational initiation factors (18); 3CLpro is the 
viral protease; and RdRp, the RNA-dependent RNA polymerase. ORF2 
encodes the capsid protein, the major structural component VP1, which also 
mediates viral entry into target cells. VP1 ranges between 530 and 555 amino 
acids and is 58-60 kDa molecular weight. The structure of GI.1 norovirus 
capsid has been resolved by X-ray crystallography, which has revealed that 
the norovirus capsid is formed by 180 copies of VP1 (19). Single VP1 is 
constituted by the shell domain designated to S and the protruding domain 
designated as P (Fig. 3b-d). The S domain spans VP1 from N terminal to 
amino acid 225. The P domain is made of the remaining amino acids and is 
divided into P1 and P2 subdomains. The P2 domain is an insertion between 
amino acids 279 and 405, and is the most variable and most exposed region 
of the VP1 protein on the virus. The P domain is also important for histo-
blood group antigen (HBGA) attachment, specifically interacting with 
fucose. It has been shown that depending on the concentration of fucose there 
are possibly up to four binding sites on the dimer of the P domain (20). ORF3 
encodes a small basic protein VP2 that is associated with virions and is 
required for capsid assembly. The VP2 is important for the stability, as well 
as functional change and nuclear localization of the VP1 (21-24). 
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Figure 3. Genome and capsid structure of human norovirus. A – human norovirus genome 
composition; B – VP1 structure; C – VP1 dimer, where one monomer is colored darker than 
another; D – virus-like particle formed of 180 VP1 monomers. Yellow – shell domain; blue – 
P1 domain; red – P2 domain (25). 
1.4 EPIDEMIOLOGY 
1.4.1 TRANSMISSION 
Norovirus is a highly contagious agent. It has been estimated that as little as 
18 particles could infect a person (26). Despite the low infecting dose, the 
yield of virus particles from subsequent vomitus and feces is significantly 
higher (27). Moreover, one recent publication has also revealed that the virus 
can be shed in stools as viral clusters enveloped within vesicles, which also 
increases the inoculum dose to the receiving host (28).   This all increases 
chances for a person to person transmission route, where contaminated fluids 
from infected individuals may reach the next person directly through fecal-
oral route or ingestion of aerosolized vomitus route. The virus can also be 
transmitted through fomites or contaminated surfaces.  
A large threat of norovirus transmission is contaminated food. This includes 
food handled by infected individuals or regular food sources like leafy greens 
(29, 30), seafood (31-33) and fruits (34, 35) washed or irrigated in 
contaminated water. Recreational and drinking water can also be a source of 
NoV (36). Outbreaks of the virus are most often related to long-term care 
facilities, but can also appear at restaurants, parties and events, cruise ships, 
military forces, schools and communities (37-44).  
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1.4.2 SEASONALITY 
Norovirus infections are also called “winter vomiting disease” due to their 
peak appearance in colder seasons. Indeed, GII.4 genotype virus caused 
outbreaks are related to winter season in Northern hemisphere and spring 
season in Southern hemisphere, which spans the months of September 
through February (14, 45, 46). However, one should also keep in mind that 
non-GII.4 viruses related infections are constantly present throughout the 
year (14), which also reflects differences in epidemiology of and/or 
susceptibility in populations to different NoV genotypes.  
1.5 SYMPTOMS 
1.5.1 ACUTE INFECTION 
The incubation time for human norovirus (HuNoV) is around 48 h and the 
disease lasts around 24 h (5). However, symptoms might be prolonged, 
especially, in very young and elderly people. One study has reported a 30-day 
mortality rate of 7% in a group of patients of average age of 77 years (47). 
Major symptoms are nausea, vomiting, abdominal cramps and malaise, but it 
can also be followed with diarrhea, anorexia, headache, myalgia, fever and 
chills (27). Though symptoms last only a few days, shedding of the virus in 
feces remains for around 29 days (27) and introduces challenges to control 
the spread of HuNoV.   
1.5.2 CHRONIC INFECTION 
There is a number of studies relating chronic norovirus infections (symptoms 
lasting >30 days) to immunodeficiencies, either primary congenital or 
secondary acquired. The chronic infection has been reported to last up to 7 
years (48) and can be difficult to control even under reduced treatment by 
immunosuppressive drugs.  The most vulnerable immunodeficient groups to 
the virus are solid organ transplant recipients, such as heart (49, 50), kidney 
(51-53), lung (54), pancreas (48) and intestine (55), as well as after bone 
marrow transplantations (56-59). The chronic infection diagnosis in the latter 
group is more challenging since symptoms might be confused with another 
common condition in such patients, i.e. graft-versus-host disease, where 
treatment of infection becomes difficult. Common variable 
immunodeficiency is the most common symptomatic antibody deficiency in 
Europeans and it is often accompanied with enteropathy (60-66). Norovirus 
has been suggested as a dominant cause of these enteropathies (67). The 
infection is also responsible for greater symptoms and histopathological 
findings in this group of patients, such as malabsorption and subtotal villous 
Gastrointestinal norovirus infections and the development of the next generation of mucosal vaccines 
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atrophy (67), which can also be confused with coeliac disease resulting in 
delayed treatment. Such infections in primary immune deficient patients lead 
to protracted diarrhea, weight loss and a need for parenteral treatment (68). 
An extended study of solid organ transplant recipients revealed that chronic 
norovirus infections could lead to shedding of the virus for months to years 
(between 32-1164 days) (69). It has also been reported that during the 
prolonged viral shedding (898 days) an intra-host evolution of norovirus has 
occurred, where at least 25 capsid protein amino acids in the virus have 
mutated (52, 70).  
1.5.3 UNUSUAL MANIFESTATION 
It has been described that norovirus infections can also be related to unusual 
set of symptom. For instance, infants have been reported to be at risk of 
central nervous system involvement (71, 72), necrotizing enterocolitis (73) 
and ileal perforation (74) related to norovirus infection. One report has 
related HuNoV infection in children with obstructive ureteral stone appearing 
as elevation of blood or urinary uric acid in urine and leading to 
nephrolithiasis (75). Other clinical reports have identified rhabdomyolysis 
(muscle breakdown) (76) and Stevens-Johnson syndrome (77) accompanying 
norovirus gastroenteritis in young children. Moreover, an outbreak among 
British soldiers in Afghanistan caused headache, neck stiffness and 
photophobia. One patient has even developed intravascular coagulation 
(Center for Disease and Prevention, 2002). Post-infectious functional 
gastrointestinal symptoms (dyspepsia, constipation and gastroesophageal 
reflux disease) have also been described as possible complications of the 
infection (78). 
1.5.4 ASYMPTOMATIC INFECTION 
Even if a person does not develop symptoms, one can still be affected with 
HuNoV. Early studies of HuNoV challenged volunteers have indicated that 
even asymptomatic individuals can develop mucosal lesions, typical to the 
gastrointestinal infection (79). Only much later after the virus discovery, it 
has been noticed that even asymptomatic individuals can be continuously 
shedding the virus (80). Asymptomatic infections can also appear among 
immunosuppressed patients (51, 52). Since it is difficult to follow 
asymptomatic infections in immunodeficient and especially in 
immunocompetent individuals, the prevalence of such infections and the 
length of shedding remain to be uncovered.  
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1.6 PATHOGENESIS 
1.6.1 HUMAN BIOPSIES 
Right after the discovery of NoV in 1972, human challenge studies helped to 
learn about the target site in human intestine upon the infection. Comparison 
of intestinal biopsies from volunteers inoculated with either Norwalk or 
Hawaii NoV revealed that, although immunologically distant strains, they 
both resulted in identical intestinal mucosal lesions of the proximal small 
intestine, which can be found already 4 hours before clinical symptoms (79, 
81). The observed mucosal lesions included altered mucosal architecture, 
mucosal inflammation and absorptive cell abnormalities. Other challenge 
studies indicated blunted villi, shortened and distorted microvilli, swollen 
mitochondria and intercellular edema with decreased activities of alkaline 
phosphatase, sucrase and trehalase (82, 83). Intestinal lesions were resolved 
in most volunteers after two weeks. Human biopsy findings were also 
consistent with HuNoV studies in gnotobiotic piglets, which have been found 
replicating HuNoV at early time points in enterocytes on the tips of the small 
intestine (84). The latest study of biopsies from immunodeficient transplant 
patients chronically infected with NoV detected viral antigen only in 
duodenal and jejunal enterocytes, but also some in the lamina propria, where 
inflammation was prevalent (85). Major capsid protein was detected in all 
segments of the small intestine. This protein was also found in macrophages, 
which was related to possible phagocytosis of infected epithelial. Finally, a 
small number of T cells and dendritic cells were found containing major 
capsid protein too. However, the significance of these finding remains 
unclear due to the limited number of sections from patient biopsies, and, 
hopefully, will be resolved in the nearest future. 
1.6.2 ANIMAL MODELS 
Chimpanzees were used to study Norwalk virus infection and immunizations 
with VLPs of GI.1 Norwalk and GII MD145 strains (86). Inoculations were 
done intravenously, which does not represent the natural transmission route 
of the virus, and immunizations were given intramuscularly. Though 
chimpanzees did not develop symptoms during the infection, it was possible 
to detect both shedding of the virus in stool and increasing antibody titers. 
Viral genome was detected in biopsies from duodenum and jejunum and, 
surprisingly, also in liver – though no histological changes could be observed 
there. Viral antigen was found in the lamina propria and related to the 
presence in dendritic cells (DC) and B cells. However, the study could be 
applied only to Norwalk virus, but not the GII genogroup virus. A lack of 
Gastrointestinal norovirus infections and the development of the next generation of mucosal vaccines 
10 
symptomatic disease presentation is limiting further studies of HuNoV in 
chimpanzees.  
Another study was conducted in newborn pigtail macaques (Macaca 
nemestrina) that were inoculated with Toronto Norwalk-like virus (87). 
These animals developed diarrhea, vomiting and became dehydrated. 
Symptoms were accompanied with viral shedding in feces, which was 
transmitted to other newborn pigtail macaques. No other non-human primate 
studies were successful in developing a HuNoV animal model (88). 
Gnotobiotic (Gn) piglets have been extensively used for HuNoV studies and 
specifically for GII.4 genotype (84, 89-94). After oral inoculation these 
animals developed diarrhea, shed virus, develop low serum and mucosal 
antibodies, and have detectable virus genome levels in the intestine. The virus 
clearly replicates in enterocytes on the tips of small intestinal villi at an early 
time point, but also some virus antigen could be found in the lamina propria 
at later time points of the infection (84). Gn piglets have also been used for 
immunization studies using P particles, though not fully successful due to a 
lack of complete protection against the virus (90). RAG2/IL2RG double 
knockout Gn piglets experienced prolonged viral antigen retention in the 
intestines and asymptomatic virus shedding (91). One study with simvastatin, 
a cholesterol reducing statin, has shown that the drug can increase the 
infectivity and the severity disease of the virus (89, 95). The Gn piglet model 
has also been used to study effects of commensal bacteria to HuNoV 
replication in vivo. The HBGA antigen expressing Enterobacter cloacae 
inhibited HuNoV replication and virus shedding, suggesting a protective role 
exhibited by bacteria (96). In contrast, Gn calves haven’t been studied as 
broadly, but they also develop diarrhea, shed the virus in stools and have 
detectable viral antigen in enterocytes and lamina propria, accompanied with 
mild histological changes in the small intestine (97). Serum and mucosal 
IgA/IgG production can also be followed in these animals. Unfortunately, 
despite all the important findings in the described animal models, further 
studies are lagging due to difficulties of getting ethical permissions for 
handling larger animals and high costs to cover.  
Currently, the only small animal model described is a recombinant activation 
gene (Rag-/-) and common gamma chain (γc-/-) deficient BALB/c mouse 
(98). The model can support GII.4 HuNoV cultures injected intraperitoneally, 
but not orally. Viral genome and antigen is present in liver and spleen, which, 
perhaps, supports the injection route, but fails to be used for further HuNoV 
pathogenesis studies.	Overall, the importance to develop an animal model to 
study HuNoV infection remains necessary.  
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1.6.3 CELL CULTURES 
Notably, most developed cell culture models are to date applied to study 
murine norovirus (MuNoV) and feline calicivirus (FCV). MuNoV does not 
cause symptoms in mice, can be easily replicated in DCs and macrophages, 
binds to terminal sialic acid (both α2,3- and α2,6- linked) moieties on 
gangliosides, requires receptor CD300lf for its infection and the entry is 
cholesterol- and dynamin-dependent, but pH independent (99-103). Further, 
in vitro infection of MuNoV can also be enhanced by bile acids. Secondary 
bile acids (GCDCA and LCA) have been shown to bind to MuNoV P domain 
and enhance its’ ability to bind to cells in a CD300lf receptor-dependent 
manner (104). Interestingly, ceramide has been shown to modify distinct 
CD300lf antibody epitope, which could lead to altered conformation and/or 
clustering of CD300lf on the cell membrane and promote viral entry (105). 
Moreover, the discovery of CD300lf receptor helped to identify a small 
population of intestinal cells called tuft cells, which can also be infected with 
MuNoV (106). FCV while coming from the norovirus family demonstrates a 
tropism and pathogenesis that differs from MuNoV. For instance, FCV 
causes respiratory infection in cats, is cultured in Crandall Reese feline 
kidney cells and binds to Feline Junctional Adhesion Molecule A (fjAM-A) 
(107, 108). The P2 domain of FCV binds the membrane domain of fjAM-A, 
which induces the conformational change in the FCV capsid and facilitates 
viral genome escape (109). FCV entry strictly requires the acidic 
environment of the endosome for uncoating, so it is clathrin-, cathepsin L- 
and pH- dependent (110, 111). Clearly, noroviruses have broadly adapted to 
infect various hosts. Hopefully, these basic discoveries will contribute to 
understanding novel and critical aspects of HuNoV pathogenesis. 
Despite clear indications of HuNoV infection targeting the small intestine, 
specifically the epithelium (79, 81-83, 85), the field has been struggling to 
get more significant evidence for the pathogenesis of the virus. Particularly, 
the reason has been a lack of success to culture the virus in classical primary 
and immortalized cells (5, 112, 113). In addition, culture systems were not 
robust or reproducible (114-119). However, recent studies have introduced 
two different cell systems to support the replication of HuNoV in vitro. Each 
of them utilizes a different cell type to support replication of the virus.  The 
first one uses a transformed murine B cell line (BJAB) and the second one 
employs intestinal epithelial cells derived from human stem cells, also known 
as human intestinal enteroids (HIEs) (120, 121). These culture systems also 
differ in the way they facilitate the infection. The BJAB system requires 
commensal bacteria producing HBGA (Enterobacter cloacae) for the virus to 
infect. Interestingly, an opposite finding has been published based on studies 
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in Gn piglets, where HuNoV infection decreased upon the exposure to the 
bacterium (96). Meanwhile, HIEs, depending on the infecting strain, 
necessitate or facilitate the infection in the presence of bile acids (121, 122) 
(Murakami et al. under review). A recent study using X-ray crystallography 
has shown that bile acids bind at partially conserved pockets on the P domain 
of some genotypes of HuNoV and stabilize P domain loops in HBGA non-
binders, as well as augment binding of GII.1, GII.10 and GII.19 (not GI.1, 
GII.3 and GII.4) with HBGA (123). However, the possibility of bile acids 
having a direct effect on the target cell under the infection of other genotypes 
of HuNoV awaits further investigations. It was also noted that NoV as a non-
enveloped virion might have adapted another form of egress than by cell lysis 
instead forming viral clusters inside extracellular vesicles (28). Such vesicles 
protect viruses from the outer exposure, still requiring the cellular receptor 
for targeting of new cells (as was shown with murine norovirus and CD300lf) 
and increasing not only the delivered infectious dose, but also the production 
of virus in infected cells. This discovery might provide some insights to the 
current cell culture models, which still need to improve the yield of viral 
titers and extensive passaging. Further work in the field is required to 
determine the cell types targeted by HuNoV under different conditions of 
host immune status and times of infection. In this way, hopefully, future 
studies of HuNoV culturing will facilitate the discovery of attachment factors 
and/or entrance receptors required by the virus.  
1.7 DIAGNOSIS 
Irrespective of presence of accompanying symptoms, infections can be 
diagnosed by laboratory analyses. Such methods focus on viral antigen and 
viral genetic material (RNA) detection. Viral particles can be detected in 
stools, vomitus, water, food and environmental specimens. Most diagnostic 
laboratories use real-time reverse transcription-polymerase chain reaction 
(RT-qPCR) to detect NoV. As diagnostic tools evolve, RT-qPCR is being 
replaced by TaqMan-based RT-qPCR, which makes the assay more sensitive 
and rapid, as well as provides both confirmation and quantitation in a single 
assay (124-126). The technique is so sensitive that it can detect as few as 10-
100 NoV copies per gram of sample. Different primer sets allow 
distinguishing between GI and GII genogroups. Furthermore, recent 
advancements in laboratory diagnostics introduced commercial platforms to 
detect multiple gastrointestinal pathogens, including GI and GII genogroups 
of NoV, which can be a distinct advantage when a fast diagnosis of the cause 
of gastroenteritis is needed, especially in immunodeficient patients (127-
129). Rapid enzyme immunoassays (EIAs) detecting NoV antigen in stool 
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samples are also worth mentioning. Unfortunately, the disadvantage of EIAs 
is their poor sensitivity, but the test may serve to rapidly generate preliminary 
results by detection of NoV during outbreaks (130). One should then keep in 
mind that negative EIA results should still be confirmed by another 
technique, as RT-qPCR. Lastly, though not a routine method, but to be 
acknowledged as an important tool in epidemiologic studies of NoV, is 
genotyping. Those laboratories, which choose to participate in CaliciNet, a 
national laboratory surveillance network for norovirus outbreaks coordinated 
by CDC in the US, submit genetic sequences of norovirus strains to the 
CaliciNet database. Thus, the database contributes to monitoring circulating 
and newly emerging NoV strains in the US. 
1.8 TREATMENT 
To date there is no specific treatment to NoV infection. However, it is 
important to replace lost fluids and electrolytes, which can be done orally or 
intravenously in special cases. It might be advisable to take antimotility and 
antisecretory agents in case of critical performance. Though no specific 
antiviral agent to control NoV infection has yet been developed, a number of 
studies focus on different antiviral strategies (131). Those studies include 
targeting of viral attachment and entry, polymerase inhibitors using 
nucleoside analogs or non-nucleoside inhibitors, protease inhibitors, and 
host-factor drugs specific to host proteins and immunomodulators. 
Nitazoxanide (NTZ), a broad-spectrum antiparasitic and antiviral drug, is 
undergoing clinical trials with controversial results. Though the drug has 
been shown to result in a broad antiviral response (132), the mechanism 
responsible for its antiviral effect is unknown. In clinical trials the drug has 
demonstrated successful treatment of both immunocompetent and 
immunodeficient patients infected with NoV. Studies have shown reduction 
in longevity of symptoms, with a complete resolution of symptoms and 
clearance of norovirus from stool samples of immunodeficient patients even 
without a reduction of the immunosuppressive drugs (133-135). In contrast, 
some case reports claim NTZ being ineffective (48, 50, 136) and the drug has 
also failed to inhibit MuNoV infection (137).  Other treatment options have 
shown some positive outcomes in immunodeficient patients using oral 
immunoglobulin (138, 139) or treatment with ribavirin (140).   
1.9 PREVENTION 
It is difficult to prevent norovirus outbreaks, because a single NoV exposure 
results in a rapid infection and subsequent rapid spread from person to 
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person. Thus, one method is primary prevention, which chases back the 
source of NoV contamination to food and water. For this, knowing the 
specific sequence of the P domain of the virus that caused the outbreak helps 
to find a common exposure source (141). Next, preventing spread from 
secondary sources, such as person-to-person transmission and contaminated 
surfaces, has been one of the challenges due to relative resistance of the virus 
to inactivation by disinfectants. The chemical resistance has been 
demonstrated in other noroviruses in the past (142) and has also been recently 
confirmed in HuNoV HIE cultures (143). The latter study implicated that 
bleaching could completely inactivate GII.4 viruses, while such a popular 
disinfectant as alcohol showed very poor affectivity in HuNoV inactivation. 
Future studies should be initiated to test other viral inactivation methods, 
such as heat and high hydrostatic pressure, to HuNoV in HIEs. Finally, 
though there are two NoV vaccine candidates undergoing clinical studies, no 
vaccine has yet been commercially approved (144-146). It is a clear 
challenge in the field to develop an effective and protective vaccine. Once the 
challenge is overcome, the most reliable tool in prevention and control of the 
virus will be introduced.  
 
 
 
 
 
 
 
 
 
 
 
Inga Rimkutė 
 
15 
2 HOST-PATHOGEN INTERACTIONS 
The role of various membrane components in viral attachment and entry to 
the host cell has been explored in a number of studies (147-151).  Viruses can 
be divided into enveloped (e.g. Adenoviridae, Herpesviridae, Retroviridae) 
and non-enveloped (e.g. Polyomaviridae, Caliciviridae). In general, the cycle 
of viral infection is divided into four steps: entry, translation, replication and 
assembly/release (Fig. 4). The early stage of viral entry into the host cell 
involves the binding of the virus to one or more cell-surface receptors 
followed by entry into the cell. Most enveloped viruses enter through 
endocytosis and/or direct penetration into the cytoplasm, while non-
enveloped use either clathrin-mediated endocytosis or clathrin-
independent/caveolin-mediated endocytic pathway (Fig. 4). Some of these 
mechanisms, such as clathrin-mediated endocytosis are ongoing, whereas 
others, such as caveolae, are ligand and cargo induced. As it will be discussed 
in this chapter, different membrane components play critical roles in 
generating the initial host-pathogen interactions contributing to the viral 
pathogenesis.   
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Figure 4. Virus cycle of infection (I) and different endocytic pathways (II) (150).  Adenoviruses 
use the micropinocytosis entry (IIA), influenza virus and arenaviruses use clathrin-
independent pathway (IIB), clathrin-mediated pathway is the most common uptake pathway 
for viruses (IIC), caveolar pathway is cholesterol-dependent and brings viruses including 
SV40, coxsackie B, mouse polyoma and Echo 1 (IID), another cholesterol-dependent pathway 
devoid of clathrin and caveolin-1 is used by polyoma and SV40 (IIE), while dynamin-2 
dependent pathway is used by Echo virus 1 (IIF). 
I.
II.
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2.1 MEMBRANE LIPIDS 
Cellular membranes are formed from a chemically diverse set of lipids. A 
high lipid diversity is universal to eukaryotes and is seen from a lipid bilayer 
to a whole organism, highlighting its’ importance and suggesting that 
membrane lipids fulfill many functions. Indeed, the correct composition and 
structure of cell membranes define key physiological and pathophysiogical 
aspects of cells. Therefore, even small changes in lipid structures and their 
composition have significant effects on essential biological functions.   
2.1.1 CLASSIFICATION 
Membrane lipids are classified into glycerophospholipids (GPLs), 
sphingolipids (SLs) and sterols (dominantly cholesterol in mammals) (152). 
Combinations of various structural components shape the chemical variety of 
GPLs and SLs. Fatty acid (FA) is one of such structural components and they 
differ in chain lengths, double bond numbers, configurations, positions and in 
hydroxylation. In fact, combinations of the two FAs, the linkage between the 
two and the head group shapes the chemical diversity of GPLs. Thus, there 
are four major GPL types: phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS) and 
phosphatidylinositol (PI). Phosphatidic acid (PA) also belongs to GPL group, 
but constitutes the smallest portion of GPLs. Their hydrophobic portion is 
diacylglycerol, which contains saturated (without double bonds) on 
unsaturated (with double bonds) FAs chains with varying lengths etc. PCs are 
distinguished by carrying the choline head group. PCs contribute to >50% of 
the phospholipids in most mammalian membranes, and have a nearly 
cylindrical molecular geometry, which forms a spontaneous bilayer with the 
lipidic tails facing each other and the polar head groups interacting with the 
aqueous phase outside of the bilayer. PEs have a relatively small head group 
– ethanolamine. PSs have a serine and tend to incorporate at least one stearic 
acid (C18:0; in the nomenclature XX:Y XX stands for the number of carbons 
in the chains and Y indicates the number of double bonds). PIs are 
characterized by their inositol head group and in most tissues predominantly 
integrate stearic (C18:0) and arachidonic (C20:4) acids.  
SLs are constituted of one sphingoid long chain base and one FA, and their 
chemical difference is determined in the length and type of sphingoid base, 
FA and head group. The major SL components in mammalian cells are 
sphingomyelin (SM), free ceramides (Cer) and glycosphingolipids (GSLs). 
While ceramide is the main backbone of SLs, the head groups differ. SM has 
a phosphorylcholine head group and GSLs contain mono-, di-, 
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oligosaccharides for their head groups based on glucosylceramides (GlcCer) 
and sometimes galactosylceramides (GalCer). Monosaccharide ceramides can 
be decorated with sulfate and, thus, compose sulfatides. Gangliosides are also 
synthesized from GlcCer and typically contain sialic acids. Sphingolipids 
have ceramides as their backbone, which vary in sphingoid bases such as 
sphinganine (d18:0), sphingosine (d18:1) or phytosphingosine (t18:0) 
dependent on ceramide synthases involved in the biosynthesis. The diversity 
of sphingoid bases contributes to the physicochemical characteristics of 
various SLs. Fatty acid part is mostly saturated in SLs and can be longer than 
in GPLs. These features allow SLs to form taller, narrower cylinders than 
PCs, which contributes to tight packing in the membrane.  
Signaling lipids are produced from hydrolysis of GPLs and SLs. Examples of 
such lipids from GPL hydrolysis are lysophosphatidylcholine (LPC), lysoPA 
(LPA), PA and diacylglycerol (DAG), and from SLs 
sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), 
ceramide-1-phosphate (C1P) and Cer.  
Cholesterol is an important lipid component of the mammalian cell 
membranes. It is composed of steroid backbone (four fused rings) and a small 
branched hydrophobic tail.  The rigid steroid backbone favors its’ interaction 
with SLs in membranes, hence, contributing to lipid rafts formation. 
Chemical features of sphingolipids allow cholesterol to get incorporated 
close to them and, thus, contribute to the integrity and dynamics of the 
membrane. The cholesterol and sphingolipid interactions in the membrane 
are explained by “umbrella model”. It says that cholesterol positions into 
regions of membranes with strongly hydrated large head groups as those 
found in sphingolipids. This way sterol rings are protected from the aqueous 
environment. In addition, the packing of cholesterol with sphingolipids is 
more likely when there are saturated FAs in sphingolipids (153). Together 
these lipids form microdomains or lipid rafts in the membrane likely 
functioning to support the physical structure of membranes and generate 
areas in the membrane specialized in lipid influx and efflux, protein 
trafficking, signal transduction and viral entry (154).  
2.1.2 SYNTHESIS 
The diversity of head groups and FAs creates the variation of more than 1000 
different lipid species (155). The synthesis of structural lipids is restricted to 
specific compartments in mammal cells. The main lipid biosynthetic 
organelle is the endoplasmic reticulum (ER).  It produces the majority of 
structural lipids, including phospholipids, cholesterol and Cer. In addition, in 
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myelinating and epithelial cells the ER synthesizes GalCer, which stabilizes 
myelin and apical membranes (156). Also, ER produces triacylglycerol 
(TAG) and cholesteryl esters, but they are non-structural molecules and we 
will leave them out. However, the ER displays low concentrations of 
cholesterol and complex sphingolipids, because these synthesized lipids are 
rapidly transported to other organelles. Indeed, significant levels of lipid 
synthesis appear in Golgi. Specifically, the later synthesis steps of SLs, which 
involves production of SM, GlcCer, lactosylceramide (LacCer) and 
oligosaccharide GSLs (157).  The majority of SLs leave Golgi to the plasma 
membrane. Thus, it is thought that the production of SLs might also have a 
role in the sorting of membrane proteins and lipids between the ER, the 
plasma membrane and endosomes through lipid rafts. Interestingly, though 
the plasma membrane is not responsible for the autonomous synthesis of its’ 
structural lipids, there is evidence provided for synthesis and degradation of 
lipids involved in signaling pathways in the plasma membrane (158).  For 
instance, sphingomyelin synthase (SMS) can contribute to the total cellular 
SM through its’ synthesis from Cer on the plasma membrane (159, 160). 
Likewise, acid sphingomyelinase (ASM) can mediate the formation of Cer 
from SM (161). 
2.1.3 FUNCTION 
Lipids have several major functions in cells, such as membrane structural 
composition, source of heat and energy, signaling molecules, protein 
recruitment platforms and substrates for post-translational protein-lipid 
modification. The major function of lipids in membranes is 
compartmentalization giving unique integrity to cells and organelles.  
Multiple functions of the plasma membrane depend on the lipid composition. 
Head group and hydrophobic tails of lipids affect the spontaneous curvature 
of the membrane. Lipids with long and saturated fatty acids, such as 
sphingolipids, make membranes thicker and less fluid owing to the tight 
packing of hydrophobic tails and stronger lipid-lipid interactions (162, 163), 
while unsaturated lipids do the opposite. It has been shown that saturated, 
unsaturated lipids and cholesterol form separate regions with high lipid 
packaging and less in artificial lipid membranes (162). This is underlying the 
lipid raft hypothesis that shows high lipid order and the ability to concentrate 
proteins (163, 164). For example, proteins like B cell receptors or 
cytoskeletal components initiate the formation of membrane heterogeneities 
on the nanoscale level and lipids have roles in stabilization of these 
microdomains and their expansion (165, 166). Also, microdomain formation 
can be supported by lipid-lipid interactions when SLs interact with 
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cholesterol through saturated hydrophobic chains and stabilize microdomains 
(163). Thus, it should be reasonable to assume that if the lipid environment is 
altered, a protein bound to the same environment may also be affected by this 
difference and thereby operate in a different manner. Furthermore, both 
leaflets of the plasma membrane contain specific lipid compositions. The 
outer leaflet contains mostly PC and SL, while the inner involves PE, PS and 
PI (167). If PS gets externalized, then its effect on many cell activities 
appears, for instance, the phagocytic clearance of apoptotic bodies (168). In 
addition, ceramide, C1P, sphingosine and S1P also act as signaling molecules 
themselves and, therefore, the dynamic alterations directly regulate many 
cellular responses raging from development and expansion to autophagy and 
apoptosis (169). Indeed, lipids have a broad spectrum of effects on cellular 
functions, but we would like to keep our focus on lipids from host-pathogen 
interaction angle.  
2.1.4 LIPID RAFTS 
Simons and Ikonen have initiated the concept of lipid rafts in 1997 (170). 
However, the biological significance of it has been debated for long time. 
Indeed, lipid raft studies have been hampered by their size, which is too small 
to resolve using conventional microscopy. Moreover, the morphology of lipid 
rafts is poorly known. Studies have been relying on chemical properties 
defining these microdomains such as insolubility in cold non-ionic detergents 
followed by flotation on sucrose-density gradients, high density and 
resistance to mechanical stress. Nevertheless, it is largely agreed that the 
presence of both cholesterol and sphingolipids is essential for the formation 
of lipid rafts in the plasma membrane. Removal of raft cholesterol with β-
methylcyclodextrin or hydrolyzing membrane sphingolipids with 
sphingomyelinase results in dissociation and inactivation of most lipid raft 
proteins (171-173). Certainly, lipid rafts control many protein-protein, lipid-
protein, protein-carbohydrate and carbohydrate-carbohydrate interactions at 
the cell surface. This is determined by the capacity of lipid rafts to 
incorporate or exclude proteins selectively, and the ability to fuse into larger 
domains. Lipid rafts are involved in protein sorting, membrane trafficking 
and signaling leading to proliferation, apoptosis, migration or adhesion (174, 
175). Therefore, it is not surprising that lipid rafts are exploited by different 
pathogens to infect host cells (147-149, 176, 177).   
The involvement of lipid rafts in caveolin-mediated pathway is indicated by 
requirement of cholesterol. This has been demonstrated using simian virus 40 
(SV40) (178-180). Indeed, SV40 requires to bind MHC class I molecules to 
enter the host cells, which is followed by internalization through the flask-
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shaped caveolae. When cholesterol is removed by chelators’ inhibitors from 
these cells, SV40 fails to facilitate the entrance. In addition, MHC class I 
molecules are hardly detected in lipid rafts of resting cells, but this membrane 
area becomes highly enriched in MHC class I molecules after the binding of 
virus. Clearly, the formation and dynamics of lipid rafts play a role in 
pathogenesis of SV40.  Interestingly, enveloped viruses have also been 
reported to be dependent on lipid rafts at the cell surface. The fusion of such 
viruses’ membrane with cellular membranes requires a conformational 
change of the virus envelope glycoprotein. It was shown that for alphaviruses 
this fusion is dependent on the presence of both cholesterol and sphingolipids 
in the plasma membrane, indicating the involvement of lipid rafts (181-183).  
Similarly, the complex binding of HIV to the cell surface appears dependent 
on lipid rafts. HIV glycoprotein gp120 first binds to CD4, which 
subsequently gathers lipid rafts enriched in co-receptors necessary for the 
entry - CCR5 and/or CXCR4 (184, 185).  Furthermore, gp120 has been 
shown to directly interact with gangliosides in lipid rafts (186). Moreover, 
sequestration of cholesterol or inhibition of the GSLs synthesis prevents the 
infection by HIV-1 in vitro and in vivo (187-191). Overall, though only a 
fraction of viral proteins have been found associated with lipid rafts, it should 
be kept in mind that more extensive identifications can be limited by the poor 
biochemical characterization of lipid raft subsets and the transient nature of 
the association (192). Hence, our detailed analysis of cellular lipid, such as 
GPLs and SLs, and protein components together with dissected glycan 
architecture of a fraction of those components supports the architecture of 
plasma membranes in humans and will contribute to future studies of lipid 
rafts and their essential roles to pathogenesis of infections, including HuNoV.  
2.2 GLYCOCONJUGATES 
Glycobiology studies structure, biosynthesis, function and evolution of 
saccharides/ carbohydrates/ sugar chains/ glycans largely distributed in nature 
and involved in numerous biological processes. The field greatly contributed 
to the structure and biochemistry of simple and complex glycans found in 
nature at the beginning of 20th century. Indeed, a number of glycobiologist 
received a Nobel prize for their achievements at that time (193). However, 
glycobiology was left in a shadow for many years and now it is gaining back 
more interest due to the development of better technologies to study the 
complexity of glycans. Apart of their well-known function in energy 
generation and metabolism, glycans inevitably have many biophysical and 
structural roles. After all glycans form a dense coating of complex and 
diverse carbohydrates found on all cell surfaces and even extracellular 
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molecules (the coating is also called “glycocalyx”). It shouldn’t be a surprise 
that, indeed, many infectious agents or symbiotic organisms tend to exploit it 
and mediate interactions with the host (194). In addition, pathogens also 
express glycans on their surfaces modulating their antigenicity. Furthermore, 
through expression of different glycosidases they can shape the glycan 
surface of the host (195). Biological roles of glycans have a broad 
classification and include a long list of functions covering such sections as 
physical structure, protection, tissue elasticity, glycoprotein folding, 
degradation and trafficking, adhesins for pathogens, pathogen recognition, 
immune modulation, antigen recognition, uptake and processing, cellular 
signaling and many more, which are nicely dissected in the latest review from 
Dr. Varki A. (196). Our contribution to glycobiology science was to explore 
binding factors on lipids and proteins possibly playing a role in the latest 
HuNoV GII.4 strain infection in the human intestinal cell cultures, as well as 
the first global lipid and proteomic analysis of human intestinal enteroids. 
Figure 5. Glycan classes in animals. Glc – glucose, GlcNAc – N-Acetylglucosamine, Gal – 
galactose, GalNAc – N-Acetylgalactosamine, Man – mannose, Fuc – fucose, SA – sialic acid, 
GlcA – glucuronic acid, Xyl – xylose. 
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2.2.1 GLYCAN BIOSYNTHESIS 
Glycosylation is catalyzed by multiple glycosyltransferases, which add 
glycans to specific substrates, specifically, proteins and lipids and other 
glycans. This process is not a template-driven process, which means that 
glycan structures are not directly encoded in the genome. Instead the 
glycosyltransferases are the primary gene products and the glycans the 
secondary gene products. Typically, glycosyltransferase activities are 
determined through their cell specific expression, specificity towards the 
substrate nucleotide donors and to the substrate acceptors. In many cases, 
glycosyltransferases deliver monosaccharides to oligosaccharides, proteins or 
ceramides in a step-by-step manner but in other cases, such as the N-
glycosylation of proteins a single large oligosaccharide is added, modifying 
the proteins just synthesized in the endoplasmic reticulum. In contrast to 
glycosyltransferases, glycosidases can remove glycans from specific 
glycosidic linkages for recycling purposes or for generating intermediates for 
other glycan synthetic steps. Hence, the overall product of the glycosylation 
depends on the availability and specificity of glycosyltransferases and 
glycosidases, and the competition between them in each cell. Furthermore, 
the biosynthesis is also affected by the availability of substrate and acceptor 
structures for different glycosyltransferases. Indeed, the regulation of glycan 
synthesis is a complex process, which generates and modulates the diversity 
of biological structures, and at the same time provides many challenges to 
glycobiology studies (193, 197-199).  Glycoengineering of cells allows the 
destruction and rebuilding of glycosylation machineries in various cells. With 
now available a highly specific gene editing by clustered regularly 
interspaced short palindromic repeat/ targeted Cas9 endonuclease 
(CRISPR/Cas9) technique it is possible to probe and dissect the roles of 
glycosylation in cell biology, pathogen-host interaction, and 
glycoengineering of therapeutic glycoproteins and biologics (200).  
2.2.2 GLYCOCONJUGATES IN BIOLOGY 
Glycoconjugates are very important compounds in biology consisting of 
glycans of varying size and complexity, covalently linked to non-glycan 
moieties like proteins and lipids. The synthesis of glycoconjugates is initiated 
in the ER, finalized in Golgi and the end product is secreted to body fluids or 
transported to the plasma membrane, which is enriched in glycolipids, 
glycoproteins and proteoglycans. Glycoconjugates can be linear or branched 
polymeric structures, where monosaccharides are usually coupled by 
stereochemical linkages, α and β. The complexity of glycoconjugate 
structures plays an important role in biological processes encoding many 
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specific biological messages in a single carbohydrate structure (196, 201, 
202).  
Glycoproteins  
More than half of all proteins are found glycosylated (203). Often 
glycoproteins carry complex mixtures of glycans, which possess the same 
protein backbone, but can differ in the glycan components and their 
attachment sites (204). Glycans are covalently attached to proteins through 
the carboxamide group of asparagine (N-linked) or hydroxyl group of serine, 
threonine or tyrosine (O-linked). The glycosylated asparagine is usually 
present in the consensus sequence Asn-X-Ser/Thr/Cys (X not Pro). N-linked 
glycans present on glycoproteins in plasma or on the cell surface affect 
protein clearance, cell adhesion, immunity and infection, which are processes 
mediated by glycan-protein interactions (205). Furthermore, they may serve 
as biomarkers and in design of monoclonal antibody production (206-210). 
N-linked glycans are also important intracellularly by promoting protein 
folding, quality control and targeting events mediated by lectins (211). The 
N-glycan structures of mature glycoproteins differ by species, cell type, 
protein and subcellular localization (212). For instance, N-linked 
glycoproteins in the ER carry high-mannose glycans and are essential in 
protein quality control (213).  In contrast, O-linked glycoproteins have not 
been studied as extensively due to challenges to study their much more 
heterogeneous structures. O-linked glycosylation is categorized into mucin 
(the attached monosaccharide residue is N-Acetylgalactosamine (GalNAc)) 
and non-mucin (the attached residue can be N-Acetylglucosamine (GlcNAc), 
fucose (Fuc), mannose, glucose (Glc), xylose or galactose (Gal)) (214). 
Mucins are the most commonly found O-linked glycoproteins in membranes 
and in secretions (215). Another common type of O-glycosylation with large 
structural diversity involves the glycosaminoglycans (GAGs). They are 
attached to proteoglycans and are long, unbranched polysaccharides. Some 
known GAG structures are dermatan sulfate, chondroitin sulfate, 
heparin/heparan sulfate and keratin sulfate. Various functions have been 
described for O-linked glycoproteins, such as importance in protein structure 
and stability, immunity, receptor-mediated signaling, nonspecific protein 
interactions, modulation of the activity of enzymes and signaling molecules, 
and protein expression and processing (216, 217). In our study we 
characterized glycoproteins from human intestinal enteroids of different 
sensitivity to HuNoV infection. N-linked glycoproteins constituted the largest 
fraction of extracted membrane proteins.  
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Glycosphingolipids 
Eukaryotic cell surfaces are enriched in GSLs, which are ceramide-linked 
glycans that can be branched and capped with Fuc and sialic acid (SA). The 
length of glycan chain can vary from one up to 60 monosaccharides in 
complex polyglycosylceramides (218, 219). More than 300 known species of 
GSLs have been characterized based on their chemical composition. In fact, 
90% of mammalian GSLs are based on glucosyl-ceramides and the rest of 
galactosyl-ceramides (220). GSLs are defined by their internal core 
carbohydrate sequence, which can be of the ganglio-, globo-, lacto- or 
neolacto- series.  Combinations of ceramide sphingoid and fatty acid parts 
add up to the diversity of GSLs. This disparate population of lipids has been 
shown to play an important role in the plasma membrane, where they are 
involved in many molecular level processes such as signal transduction, cell 
adhesion, modulating growth factor/hormone receptor, antigen recognition 
and protein trafficking. All these functions or their dysfunctions may 
contribute to pathogenesis of different illnesses like infectious diseases, 
lysosomal degradation and storage disorders (GSL storage disorders), 
neurodegenerative diseases, multiple sclerosis, cancer and diabetes (221, 
222). To conduct our norovirus binding studies, we focused on intestinal 
GSLs decorated with histo-blood group antigens, which might be important 
attachment factors for the virus infection.  
2.2.3 THE ABO(H) AND LEWIS HISTO-BLOOD 
GROUP SYSTEMS 
Karl Landsteiner discovered the ABO blood group system on erythrocytes in 
1900 and the structure of these carbohydrate based antigens was defined by 
Walter Morgan after 50 years (223). Later, it was realized that these antigens 
are also found in epithelium of gastrointestinal, respiratory and urogenital 
tracts, as well as in body fluids like saliva. Thus, the terminal glycan epitopes 
are produced through tissue specific glycosylation of glycosphingolipids and 
glycoproteins are termed as histo-blood group antigens (HBGAs) (224). 
Genes encoding specific glycosyltransferases determine the composition of 
these antigens. Therefore, all individuals present HBGAs on their cell 
surfaces depending on the activity of the responsible glycosyltransferases.   
Biosynthesis of HBGAs 
The synthesis of HBGAs is coordinated by a set of glycosyltransferases 
specific to the respective blood groups (225, 226). The ABH and Lewis 
HBGAs are closely related and presented as terminal carbohydrate structures 
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on glycolipids and glycoproteins. Importantly, the HBGAs vary based on the 
precursor such as type 1 (Galβ1,3GlcNAcβ1-R), type 2 (Galβ1,4GlcNAcβ1-
R), type 3 (Galβ1,3GalNAcα1-R) and type 4 (Galβ1,3GalNAcβ1-R). The 
type 1-3 chains are common among both glycolipids and glycoproteins, while 
type 4 chains can be found only in glycolipids. Although the ABO epitopes 
can be expressed on all 4 precursors, the Lewis epitopes are found only on 
type 1 and type 2 lacto- and neolactoseries of glycans.  
ABH antigens 
It is important to define ABO as a histo-blood group system, where 
individuals can be grouped into O, A, B and AB blood groups based on the 
antigen presentation. These individuals would carry H, A, and B antigens 
composed of distinct oligosaccharides. The synthesis of A and B antigens is 
determined by A and B transferases encoded by the ABO gene. 
Polymorphism of the ABO gene explains the differences of the ABO blood 
groups.  
The H antigen is defined by a terminal α-1,2-fucose residue formed by the 
action of α-1,2-fucosyltransferases 1 (α2FucT1) and 2 (α2FucT2). The 
α2FucT1 is found active in erythroid and vascular endothelial cells, and 
predominantly on the type 2 and 4 chains. The α2FucT2 is found active in 
secretory cells and epithelia of gastrointestinal, respiratory and urogenital 
tracts with higher preference to the type 1 and 3 chains (227). Interestingly, 
some type 2 chain activity has also been reported for the α2FucT2 (226, 228). 
These transferases are encoded by the FUT1 and FUT2 genes, respectively. 
Complete lack of H is very rare, but is commonly known as the Bombay 
phenotype and is determined by inactivity of both FUT1 and FUT2 genes. 
There can also be a weak expression of H, referred to as the para-Bombay 
phenotype, and resulted by FUT1 mutations. Since the FUT2 gene is still 
active in para-Bombay individuals the H antigen is found in secreted fluids 
and other locations than the red blood cells (229-232).  The H is found in 
high amounts in group O individuals and in low amounts in group A, B and 
AB individuals since the H antigen is then converted into A and/or B 
antigens. 
The A and B antigens are constructed by glycosyltransferases encoded in 
ABO gene. The allele at ABO locus encodes α1,3-GalNAc transferase, which 
adds α1,3-GalNAc to the Galβ on the H epitope resulting in the A antigen. 
Similarly, the B allele encodes α1,3-Gal transferase and gives rise to the B 
antigen. The O allele encodes for an inactivated/truncated form of the A or B 
glycosyltransferase. Thus, individuals of blood group A express at least one 
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A allele at the ABO locus (genotype AA or AO) and B blood group 
individuals express at least one B allele (genotype BB or BO). Individuals of 
genotype AB are classified into AB blood group. Those who belong to the 
blood group O have both alleles of ABO locus inactive (genotype OO) and 
do not express neither A nor B antigens. A and B glycosyltransferases are 
specific to the H precursor structure of type 1, type 2, type 3 or type 4 (233). 
The biosynthesis of A/B antigens on type 1 chains depends on the expression 
of FUT2 gene and the biosynthesis on type 2 chains requires the cellular 
expression of either FUT1 or FUT2 genes (225, 226, 228, 234).  
The FUT1 and FUT2 genes are closely linked and located on chromosome 
19q13.3 (235). Mutations in FUT2 gene result in the absence of ABH 
antigens in secretory fluids and such individuals are called non-secretors (se). 
However, when the FUT2 gene is expressed, the ABH antigens is produced 
and individuals are called secretors (Se). The most common mutation in 
FUT2 among Europeans is the G428A non-sense mutation and every fifth 
individual of the Caucasian population is estimated to be a non-secretor, 
while the G571T mutation is more likely to be found in Asia and Pacific 
Islands (236, 237). Several other mutations among various ethnic populations 
have been also identified, but are considered to be rare (227). However, the 
frequency of non-secretors differs significantly among different populations 
and could be related to the genetic diversity of various pathogens adapted to 
infect the host. For instance, the P[6] rotavirus strain has been shown to adapt 
to a predominantly Lewis negative population in Africa and be responsible 
for the majority of rotavirus infections there, while the P[8] strain does not 
infect Lewis negative individuals and is targeting the secretor and Lewis 
positive population in the Northern hemisphere (238).  
Lewis antigens 
Lewis antigens are named after a clinical case of Mrs. Lewis first reported by 
Arthur Mourant in 1946 (239). Soon it was suggested that the new Lewis 
antigen group is the result of the interaction of two genetically independent 
loci, Lewis (Le/le) and secretor (Se/se) (240). The final product is determined 
by the presence of α1,4- or α1,3-fucose on the GlcNAcβ of type1 or 2 glycan 
chain, respectively,  on glycolipids and glycoproteins (225, 226, 241).  
The biosynthesis of type 1 Lewis antigens is carried out by an α1,3/α1,4-
fucosylransferase 3 (α3/4FucT3) encoded by FUT3 gene. This enzyme adds 
α1,4-Fuc to GlcNAcβ on either the type 1 chain precursor or the type 1 H 
antigen resulting in Lewis a (Lea) or Lewis b (Leb) antigens, respectively. Lea 
and Leb antigen biosynthesis is mainly restricted to the epithelia, which 
Gastrointestinal norovirus infections and the development of the next generation of mucosal vaccines 
28 
express both the α3/4FucT3 and the α2FucT2. This means that these type 1 
chain antigens can also be found in soluble form in secretions and body 
fluids. However, erythrocytes do not synthesize these antigens themselves, 
but they gain Lewis antigens through passive adsorption of Lewis positive 
glycosphingolipids (242), which circulate in lipoprotein complexes in the 
plasma. Historically, only glycan structures on the type 1 chains were called 
Lewis antigens, but later the term was adapted for other type chain structures 
too. Adding to the complexity of the Lewis type of antigens is that the type 1 
chain precursor is sometimes called Lewis c and the H type 1 chain is 
sometimes called Lewis d.  
Nevertheless, important to note that individuals who lack the active 
fucosyltransferase encoded by FUT3 gene (lele) are called as Lewis negative 
and express phenotype Le(a-b-). There is a number of point mutations 
leading to inactive FUT3 gene, among those the most common are C314T or 
T202C (243, 244). Individuals who have at least one functional allele at 
FUT3 locus (Lele or LeLe) are known as Lewis positive with the phenotype 
Le(a+b-) or Le(a-b+), corresponding to non-secretors or secretors, 
respectively. A third group of individuals with the phenotype Le(a+b+) is 
common in Asian populations and are called weak-secretors/partial secretors 
due to partially inactivating mutations (245). 
When the α3/4FucT3 adds α1,3-Fuc to the type 2 chains precursor or the type 
2 H determinant, isomers of Lewis structures are formed such as Lexis x 
(Lex) and Lewis y (Ley), respectively. Other fucosyltransferases than 
α3/4FucT3 can also add the α1,3-Fuc and, thus, generate the type 2 Lewis 
antigens. In addition to the FUT3 gene, they are encoded by FUT4, FUT5, 
FUT6, FUT7, FUT9, FUT10 and FUT11 genes. The fucosyltransferases 
encoded by FUT3 and FUT5 genes show activity for both α1,3- and α1,4-
fucosylation, but the gene product of FUT3 preferentially fucosylates type 1 
chains and the product of FUT5 has the preference to the type 2 chains (246-
250). Interestingly, other fucosyltransferases encoded by FUT4, FUT6, 
FUT7, FUT9, FUT10 and FUT11 are restricted to type 2 chains, but they also 
possess unique acceptor specificities (251-255).  The FUT7 encoded product 
would transfer α1,3-fucose only on the α2,3-sialylated type 2 precursor 
resulting in sialyl Lewis x structure, while the FUT4 coded enzyme would 
add α1,3-fucose only on the internal GlcNAc in polylactosamine chains (256, 
257).  
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Figure 6. Biosynthesis of HBGA antigens. GalNAc – N-Acetylgalactosamine; Gal – galactose.  
Function of HBGAs 
Traditionally, majority of research of blood group antigens has focused on 
understanding blood transfusions. However, HBGAs are primarily tissue 
antigens and are widely distributed throughout the body. Antibodies to these 
tissue antigens can cause rejections of transplants and can cause spontaneous 
abortions (258).  Furthermore, growing evidence points to the involvement of 
HBGAs in infectious diseases, tumor immunology and membrane chemistry 
(258, 259). Unfortunately, some challenges in the field hamper its’ faster 
development. For instance, most studies have been related to only the ABO 
phenotype, but seldom to the combination of ABO, secretor (FUT2) and 
Lewis (FUT3) geno- and phenotypes. Moreover, animal models differ from 
humans by their antigen glycosylation structures, which have turned 
researchers into strenuous efforts of humanizing these model systems 
attempting to overcome the species barrier. This is particularly difficult when 
studying epithelial cells facing the exterior milieu of various infectious 
agents. Other strategies have turned into molecular biology techniques or 
computer modeling. Our study has also taken a step forward in HBGA 
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research field by analyzing pure GSLs and their binding kinetics to norovirus 
virus-like particles in artificial bilayer membranes. Furthermore, we also 
studied human intestinal enteroids, which can grow in vitro and resemble 
small intestine epithelium individually. Indeed, these cells are well suitable 
for host-pathogen interaction studies too and should add more to the 
understanding of the HBGA function on the human cell surface in the future.  
Epithelial cells express ABH and Lewis antigens, which are effectively used 
by parasites, bacteria and viruses as receptors for attachment resulting in 
different susceptibilities depending on the antigen profile of an individual 
(260). Thus the polymorphism of ABO, FUT2 and FUT3 genes in humans 
ensures the protection from certain infections of part of the population. Some 
individual could be susceptible to one type of pathogen, yet would be 
resistant for another type of pathogen that uses a distinct carbohydrate 
receptor. For example, Helicobacter pylori adhesin (Blood group binding 
Adhesin: BabA) binds to Leb antigen present on human gastric and duodenal 
mucosa. However, the binding is lost upon the addition of terminal GalNAcα 
(the blood group determinant) suggesting that the availability of H.pylori 
attachment factors might be reduced in blood group A and B phenotype 
individuals, and opposite in blood group O (261, 262).  Similarly,	rotavirus	P[11] VP4 has been observed to exhibit tropism for neonates. This virus has 
been shown preferentially bind to the H type 2 HBGAs indicating that glycan 
modification during neonatal development may mediate the age-restricted 
infectivity of neonatal viruses (263). Importantly, and also the focus of this 
thesis, FUT1 and FUT2 polymorphisms have also been shown to play a role 
in viral infections, including caused by caliciviruses (264-269). The diversity 
of FUT3 gene is also important in the development of some infectious 
diseases (270). 
2.3 HUMAN NOROVIRUS AND ATTACHMENT 
FACTORS 
2.3.1 NOROVIRUS-GLYCAN INTERACTIONS 
Noroviruses engage glycans as essential attachment factors to promote 
infection of host cells. In the last years cell cultures, animal models, structural 
biology and biophysics have significantly contributed to our understanding of 
norovirus-glycan interactions. Structural work and biophysical techniques 
targeting membrane-attached glycans have indicated that a static picture of 
glycan recognition is not enough. However, it remains a challenge to link 
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biophysical observations to biological nature of norovirus entrance into the 
host cell.  
Binding studies to HBGAs 
It was early observed that GI.1 HuNoV VLPs bind to gastroduodenal 
epithelial cells carrying H antigen on the type 1, but not the type 2 chains 
(271). Later, norovirus VLP binding studies have been based on classical 
enzyme-linked immunosorbent assays (ELISA), where the plate surface 
would typically be coated with pig gastric mucins, saliva or neo-
glycoproteins carrying definite HBGA structures (272-275). These simplistic 
studies elucidated the distinct binding preferences between the GI and GII 
genogroups. Specifically, the GI strains preferentially bind to the A antigen, 
while the binding patterns of the GII genogroup are more complex and are 
specific for specific strains. For instance, the GII.4 strains require secretor 
gene dependent HBGA structures, while the GII.3 genotypes exhibit less 
clear patterns with a better recognition of A and B antigens (275, 276). 
Interestingly, evolutionary analyses of GII.4 norovirus strains over the period 
of 1987 to 2005 could identify different binding properties for the same GII.4 
genocluster over the period of 20 years (274). The study employed GII.4 
VLPs from 5 representative evolutionary clusters and evaluated their binding 
to saliva from secretors and non-secretors. Similarly, another group 
conducted HBGA binding studies with 6 different GII.4 norovirus strains 
from 1987 to 2007 and also found binding patterns differing among the GII.4 
strains over the time (277). Interestingly, the GII.4 variants identified after 
2002 have evolved the ability to bind non-secretor Lewis HBGA, which 
could explain the high prevalence of this genotype (278). Clearly, GII.4 
noroviruses and, possibly, other noroviruses have undergone an evolution, 
which has allowed them to change amino acid composition of their binding 
site in order to escape host immunity under the selection pressure from 
different HBGAs in different human populations.  
Although strong evidence has been implicating ABH antigens in human 
norovirus infection, additional evidence has been reported suggesting that 
other co-factors may exist, at least for specific strains (279). In addition, 
some reports have indicated that some norovirus strains (GI.3 and GII.1) fail 
to bind to any of the available synthetic HBGAs or saliva glycoproteins, 
which suggests that additional factors may be involved in norovirus binding 
(25, 276, 280). In fact, heparin sulfate, citrate, sialic acid and GalCer have all 
been shown to bind HuNoV (281-284). Furthermore, human milk 
oligosaccharides, which are naturally occurring in human milk and usually 
carry HBGAs, have been shown to bind human norovirus (285, 286). All the 
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additionally identified co-factors, such as bile acid in GII.3 infection 
(121)(Murakami et al., manuscript in preparation), represent a complicated 
norovirus cell entry process and could possibly contribute to the future 
treatment, detection and control strategies against specific norovirus strains. 
Crystal structure analysis has been the most important method for delivering 
information about norovirus-glycan attachment at atomic resolution. 
However, so far only the intact capsid of GI.1 HuNoV virus has been 
determined with crystallography (19). The other crystallography studies have 
been based on P domains. Nevertheless, one recent study used P domains of 
three different GII.4 variants to co-crystallize them with a panel of HBGAs, 
including both type 1 and type 2 structures (287). Many HBGA-P domain 
interactions involved complex binding mechanisms to HBGAs that were not 
observed before with identical P domains in ELISA.  Indeed, these new data 
provide new insights for improving HBGA binding assays in order to 
increase our understanding about norovirus and HBGA interactions.  
Other assays have been used to investigate the binding of HBGAs to 
noroviruses, particularly, the dynamics between glycan-norovirus capsid 
protein to answer how glycan attachment modulates molecular protein 
dynamics (288).  Such affinity data can be extracted from saturation transfer 
difference nuclear magnetic resonance (STD-NMR) experiments, native mass 
spectrometry (MS), surface plasmon resonance (SPR), atomic force 
microscopy (AFM), quartz crystal microbalance with dissipation (QCM-D), 
and total internal reflection fluorescence microscopy (TIRFM). STD-NMR 
experiments have emerged as a very robust tool to identify and characterize 
the ligand binding. This technique is able to discriminate between the binding 
and non-binding ligand and to deliver the ligands’ binding epitope. Recently, 
these experiments have been extensively employed to characterize binding of 
HBGAs to noroviruses and other caliciviruses. For instance, it’s been 
suggested that the binding of HBGAs to GII.4 (Saga, Ast6139) and to GII.10 
(Vietnam026) capsid proteins is a more complex process involving 
cooperative binding events (289).  The native MS method has been used to 
determine the stoichiometry of complexes of HBGAs with norovirus P dimer 
showing that the inner fucose binding pockets may not be available for the B 
antigen because the binding to these sites would lead to steric clashes with 
the protein (290). Thus, there might be lower affinity HBGA binding sites yet 
to be discovered. However, not many studies address glycan-norovirus 
interactions using the SPR, but a recent study has reported binding of 
sialyllactose to P-dimers, which was complimented in NMR experiments 
(291).  
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Additionally, more emphasis should be given to the presentation of HBGAs 
as part of membrane components. QCM-D is useful to determine the binding 
affinity of VLP to glycolipid in the model membrane, as shown before (292) 
and in one of the papers included in this thesis. Recent studies highlight that 
membrane embedding of glycans has a huge impact on norovirus attachment 
(284, 293-296). A study by Rydell et al. also demonstrated the formation of 
membrane invaginations of giant unilamellar vesicles containing 
glycosphingolipids with different HBGAs induced by GII.4 VLP binding 
(296). Furthermore, studies using a model membrane system containing pure 
GSLs and employing TIRF microscopy allow VLP binding analyses in more 
complex systems of membranes and cells (284, 293-295, 297).   
Carbohydrate binding sites 
Noroviruses bind HBGAs in the P domain of their capsid protein VP1 (276, 
278, 298). The binding sites of HBGAs to P domain structures from GI and 
GII noroviruses are distinct in the location and structural characteristics (Fig. 
7) (298, 299). This shouldn’t be a surprise since GI strains primarily bind to 
the galactose of the disaccharide precursor and the GII strains bind to the 
fucose residue of the HBGA. Furthermore, the HBGA binding pocket could 
be divided into two sites, where site 1 is binding the glycan residue and site 2 
is constantly evolving due to its’ susceptibility to sequence and structural 
alterations, thus allowing the HBGA binding to be strain-specific (278, 300). 
For example, sequence changes in site 2 of the GII.4 variants after 2002 have 
modulated the ability to bind also to the Lea antigen (278). In addition, 
several studies have shown that depending on the fucose concentration, the P 
dimers of GII.4 (MI001), GII.4 (Saga) and GII.10 can increase the number of 
bound fucoses from two to four (20, 291, 301). Interestingly, crystal 
structures revealed that both the secretor and Lewis fucoses can bind to the 
same canonical fucose binding site, but the genotype determines if the 
secretor (as for GII.10) or Lewis fucose (as for GII.4 Saga) will bind to the 
pocket (287).  Moreover, flexible loop residues from 391 to 395 on the GII.4 
P dimer can also help the Lewis antigen to bind (287). Finally, lately it was 
reported that the GII.4 P domain can be affected by a post-translational 
modification, which causes a transformation of amino acid asparagine in an 
antigenic loop adjoining the binding site, thus, resulting in decreased affinity 
to HBGA structures (302). This likely demonstrates the multistep evolution 
of noroviruses to adjust to the diversity of hosts and to escape from immune 
responses, and may be a critical part in the infectious process after adhesion.  
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Figure 7. HBGA recognition by GI and GII noroviruses. A, Superimposed GI (grey) and GII 
(green/slate) P domains in complexes with H-pentasaccharide (green sticks) and A-
trisaccharide (cyan sticks), and A-trisaccharide (yellow sticks), respectively. Close-up 
interaction views of GI NoV P domain with H type 1 pentasaccharide (green sticks) and A-
trisaccharide (cyan sticks) in B. H-1 residues are labeled in italics, H bonds are indicted by 
red dashed lines, and the hydrophobic interaction to Trp with yellow circles. The GalNAc of A 
antigen partially mimics the interactions of the H-1 fucose. C, close-up view of GII NoV P 
domain interacting with A-trisaccharide (yellow sticks). The domain is anchored to fucose, 
while the GalNAc residue provides only limited contacts (151). 
2.3.2 VIRAL TROPISM 
There is a collected knowledge upon the relationship between histo-blood 
group antigens (HBGA) and norovirus and rotavirus (271, 296, 299, 303-
309). The latter two pathogens are responsible for the largest numbers of non-
A
B
C
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bacterial gastroenteritis worldwide.  NoV may serve as the most suitable 
example of viral-host cell interaction based on ligand-HBGA binding. Very 
early observations from NoV challenged individuals pointed to different 
populations prone to develop the disease (310, 311). A part of challenged 
individuals would develop clinical symptoms of gastrointestinal 
inflammation, while another part would remain asymptomatic. Antibody 
response between two groups would differ too. Symptomatic ones would 
have higher levels of serum antibody titers than asymptomatic, but those 
would not protect from re-challenges after 1-2 years. Clearly a key factor 
allowing some individuals to remain NoV infection resistant was missing. 
Finally, a hint appeared in the literature when it was published that NoV-like 
particles induce hemagglutination of red blood cells from different blood 
groups (312). Then the first report of NoV disease association with ABO 
HBGA type followed, where it was stated that individuals with O phenotype 
are more likely to be infected with NoV (303). That study was based on 
individuals challenged with NoV GI.1 Norwalk strain and gave rise to many 
other studies about the relationships between NoVs and HBGAs. Finally, the 
publication came pointing to the importance of secretor status to NoV 
binding on gastrointestinal epithelial cells (271). After one year 4 distinct-
strain specific patterns of NoV binding to HBGA family could be described 
(313), which brought a wider picture of a complicated complexity among 
NoV strains leading to infection. Finally, a study conducted by Harrington 
and colleagues confirmed NoV attachment to HBGAs (305). Thus, the 
importance of this virus-ligand interaction became evident. Having a fast 
development of NoV-like particles production, a greater variety of VLPs 
binding studies could be performed. Four binding patterns were extended to 
six and today there are 7 binding patterns identified (Table 1)(276). For 
instance, we have a group of viruses preferably binding to A and O secretors 
only (NoV GI.1). Another group would bind to A, B and O secretors (GII.4, 
VA387) or A, B secretors binders (GII.5, MOH), or even Lewis positive 
secretors and non-secretors (GII.9, VA207). The viral attachment ability has 
been developed so well that we would not find any individual HBGA pattern 
unrecognized by any of NoV strains. To top up a beautiful diverse attachment 
pattern of NoV, there are some strains identified as non-recognizers of any 
fucosylated HBGAs (GI.3 (Desert Shield virus; VA115), GII.1) (25, 276, 
280). For a long time the field lacked a direct experimental system to test 
whether the infections caused by NoV were indeed dependent on host cell 
HBGAs. Since 2016 human NoV infection is possible to propagate in tissue 
cultures in laboratory settings (121), which opened a door for advanced 
studies upon HuNoV and host cell interactions. 
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Table 1. Norovirus binding patterns to HBGAs. 
Norovirus 
variant 
A/B H Le 
GII.4 VA387 + + - 
GII.4 GrV + + - 
GI.1 Norwalk + + - 
GI.2 C59 + + - 
GII.3 PIV + +* - 
GII.3 MxV + +* - 
GII.1 Hawaii  + +* - 
GII.5 MOH + - - 
GII.2 BUDS + - - 
GII.2 SMV + - - 
GI.8 Boxer - + + 
GII.9 VA207 - +* + 
GII.13 OIF - - + 
GI.3 DSV - - - 
GI.3 VA115 - - - 
Binding groups are coded in colors. * Positive signal for binding, but not strong (276). 
FUT2 polymorphism in susceptibility 
Earlier studies have shown that some individuals after challenge with high 
doses of virus remained resistant to the disease (303). Whether these 
individuals were just symptom-free or uninfected due to an innate resistance 
or pre-existing immunity to NoV remained questionable. There could be 
several factors determining the susceptibility to infection with enteric 
pathogen such as genes encoding molecules mediating attachment, 
recognition of pathogen, inflammatory cytokine responses, innate and 
acquired immunity (314). Similar resistance patterns were detected in wild 
rabbits, where rabbit hemorrhagic disease virus (RHDV) is a highly virulent 
calicivirus that has become a major cause of mortality in wild rabbit 
populations (315). Early challenge studies on GI.1 virus have implicated that 
non-secretor individuals were resistant to norovirus infection, while most of 
the secretor individuals got infected (316-318). Similar secretor driven 
susceptibility was observed in the GII.4 challenged volunteers, where all non-
secretor individuals remained symptom-free, thus, protected from the disease 
(319) Moreover, outbreak studies from Sweden, Denmark and China 
following norovirus GI.6, GII.6 and GII.4 caused infections, could all report 
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that, indeed, symptomatic individuals were restricted to the secretor status 
(320-322). These studies, as well as the analyses of serum antibody 
prevalence and titers of individuals with different ABO, Lewis and secretor 
status (323), clearly demonstrated that the secretor status, dependent on the 
FUT2 gene polymorphism, is a factor determining the susceptibility to the 
virus (324, 325). The latest genome wide association meta-analysis by 
Bustamante and co-workers additionally suggested a new FUT2 allele 
mutation variant W152X significantly associated with diarrhea under age of 1 
(325). It remains unclear how this variant would be related to NoV infection, 
but the study has implicated the importance of FUT2 gene in diarrhea in 
young children from any population. However, there is still a lack of 
evidence for a full protection to NoV infection related to any one of the 
FUT2 mutations (266, 316, 324, 326-330), especially considering the big 
diversity of NoV strains that has developed over the years. Study by Larson 
and colleagues extended the previous knowledge focused on secretors and 
showed that ABO phenotype and Lewis genotype does not correlate with 
antibody prevalence and titers against NoV GII (267), which still does not 
exclude the importance of the latter in the viral-host attachment pathogenicity 
for single strains. The secretor status has lately been shown to be of major 
importance in susceptibility to GII.4 human norovirus (HuNoV) replication 
in human intestinal enteroid cultures (HIE) (121). 
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3 VACCINE DEVELOPMENT 
3.1 PROTECTIVE IMMUNITY 
Vaccines represent one of the greatest achievements of modern medicine. 
Despite their success, a majority of vaccines have been developed 
empirically, with little or no understanding of the detailed mechanisms by 
which they convey resistance against infection. The most important function 
of the immune system is to protect us from pathogens. Immune protection 
rests on both innate and adaptive immune responses, and the interaction 
between the two. Since adaptive immunity is epitope specific and has long-
term memory, it is the ultimate target to be achieved by an effective novel 
vaccine. Recent advances in innate immunity have offered new insights about 
the mechanisms of vaccine-induced immunity and have facilitated a more 
rational approach to vaccine design. Immune protection can be achieved 
through stimulation of neutralizing antibodies (331). In fact, antibodies are 
good correlates of protection against many pathogens, including viruses, such 
as influenza (332, 333), rotavirus (334), and norovirus (316, 335-337). 
However, also cell-mediated immunity against these virus infections have 
recently been ascribed critical roles. For example, there is growing evidence 
that a key protective role is played by tissue-resident memory T cells. Both 
cytotoxic CD8 T cells and effector CD4 T cells can develop from these 
tissue-resident memory cells as found in protection against influenza 
infection (338). Indeed, even in the complete absence of antibodies lung 
memory CD4 T cells could be broadly protective as observed in an 
experimental model of vaccination against influenza. Also, protection against 
HIV infection or malaria relies not only on specific antibodies, but requires 
strong T-cell responses (339, 340). Therefore, vaccine development today is 
aimed at stimulating antigen-specific antibodies as well as tissue resident 
memory T cells that persist long time after vaccination. 
Naïve T cells are activated by dendritic cells (DCs) in lymphoid organs. DCs 
are the professional antigen-presenting cells (APCs) for priming of T cells. 
Upon antigen (Ag) exposure, the DC will internalize the Ag by phagocytosis, 
pinocytosis or receptor-mediated endocytosis, and subsequently the Ag is 
digested into peptides, which will be presented on human leukocyte antigen 
(HLA) -DP, -DQ, -DR/ major histocompatibility complex (MHC) class II 
molecules expressed on the surface of the DCs, B cells and other APCs. It is 
known that mostly peptides with a high affinity for the MHC class II 
molecules can effectively prime T cell responses. Virus proteins, produced 
inside the infected cell, are displayed on HLA-A, -B, -C/ MHC class I 
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molecules, which are recycled to the surface of the cell, and, thereby, can 
prime CD8 T cell responses. The HLA/MHC molecules are capable of 
binding many different peptides and since each individual can carry 3 
different HLA /MHC molecules of the class I and class II types, this leads to 
an impressive combination of isoforms, which contribute to increasing the 
diversity of HLA molecules of each individual. These divergent and complex 
panels of HLA/MHC molecules are responsible for the broad ability to 
always find epitopes that can trigger an immune response against the many 
diverse pathogens we can encounter.  In this thesis work we have focused on 
MHC class II molecules, and presentation of peptide Ags that result in 
priming of CD4 T cells and antibody responses.  
CD4 T cells or T helper cells (Th) express the CD4 co-receptor and the T cell 
receptor (TCR), which recognizes complexes of peptides and MHC class II 
molecules on the antigen-presenting cells (APCs). When the T cell is 
activated in the draining lymph node, it can differentiate into one of several 
effector subsets of Th cells dependent on the microenvironment at the 
inductive site. The most important CD4 T cell subsets include Th1, Th2, 
Th17, T follicular helper cells (Tfh) or regulatory T cells (Treg). Each of 
these subsets is functionally distinct and defined by their cytokine production 
(341). Th1 development is dependent on IFN-γ	 and	 IL-12. These cells are 
producers of IL-2 and the most important producers of IFN-γ. Their function 
is to provide cell-mediated immunity against viruses and intracellular 
bacteria, as well as support B cell differentiation to antibody production. For 
Th2 development we require the IL-4 cytokine, which plays a critical role 
against helminthic parasites infections through secretion of IL-4, IL-5 and IL-
13. Th17 cells develop when IL-6, IL-23, IL-21 and transforming growth 
factor (TGF)-β are present in the microenvironment at the inductive site. 
Th17 cells can make IL-17, IL-21 and IL-22, and they protect against virus, 
bacterial and fungal infections. Tregs differentiate in the presence of TGF-β, 
which is a cytokine they also produce along with IL-10. The Tfh subset is 
involved in regulation of the B cell response in the germinal center (GC) of 
the draining lymph node. These cells produce cytokines that are critical for B 
cell isotype differentiation also called immunoglobulin class-switch 
recombination (CSR) and IL-4, TGF- β or IFN-γ can drive B cell IgG1, IgE, 
or IgA production. IL-21 is influencing differentiation and maturation of 
activated B cells into B memory cells and long-lived plasma cells in the GC.  
CD8 T cells or cytotoxic T lymphocytes (CTLs) have the CD8 co-receptor 
and react to peptides presented by MHC I class molecules, which are 
expressed by all nucleated cells in the body. These cells are essential for cell-
mediated immunity against intracellular pathogens and produce IFN-γ, TNF-
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α, perforins and granzymes.  
Figure	8.	Activation	and	function	of	T	cell	subsets.	 
Importantly, some activated T cells develop into memory T-cells and play a 
protective role against future infections with the pathogen (342-344). For 
both CD4 and CD8 T cells there are three main subsets of memory cells: 
central memory (TCM), effector memory (TEM) and tissue resident memory 
T cells (TRM). TCMs express the C-C chemokine receptor type 7 (CCR7), 
which allows the cells to home to and remain in the secondary lymphoid 
organs where the CCR7 ligands CCL19 and CCL21 are produced. These 
cells rapidly respond to reactivation by the specific Ag. On the other hand, 
TEMs and TRMs lack CCR7, and are re-circulating (TEM) or reside in the 
tissues (TRM), and respond more rapidly to reinfection. They display effector 
functions by producing granzyme B or IFN- γ, at an early stage of infection 
(345, 346). The memory T cells can survive for decades with a half-life of 8-
15 years providing long-lasting protection against reinfection (347).  
Production of antibodies depends on the simultaneous induction of Tfh cells 
that support the GC reaction in the draining lymph node. Thus, the B cells 
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need helper factors to proliferate and differentiate into memory B cells and 
plasma cells for antibody production. The B cell receptor (BCR) binds 
specifically to the Ag, which in most cases are 3D structures that constitute 
the conformational epitopes. After binding, the BCR conveys signaling and 
the Ag can be endocytosed and degraded into peptide. These can then be 
presented on MHC II molecules to activated CD4 T cells that at the T-B cell 
border in the lymph node initiate production of helper factors, such as 
cytokines and CD40L expression by the CD4 T cells. This interaction leads 
to strong expansion of the B cell clones and their differentiation to memory B 
cells and long-lived plasma cells. B cell memory can be long-lived and may 
last for a lifetime. For example, immunity against smallpox has been shown 
to persist for more than 70 years in vaccinated individuals. Thus, even though 
smallpox was eradicated more than 30 years ago the memory B cell clones do 
not appear to require the presence of Ag (348).   
3.2 EVOLUTION OF VACCINES 
The world’s first vaccine was developed by Edward Jenner against smallpox 
and it is an example of a live attenuated vaccine. Such vaccines consist of the 
living microorganism that has been made less virulent than the pathogenic 
strain and, hence, can provide a high level of antigen exposure, albeit not 
leading to severe infection. The smallpox vaccine has eradicated the disease. 
Also, other live-attenuated vaccines such as those against measles, mumps 
and rubella have been successful. These vaccines provide endogenous 
immunoenhancers, also called adjuvants, and, therefore, do not require the 
addition of such elements.  Adjuvants are molecules with strong recognition 
by the innate immune system and these are derived from, for example, the 
bacterial cell wall or genomic nucleic acid, which are recognized by the 
innate cells by pattern recognition receptors (PRRs).  
A risk with live attenuated vaccines is that they can revert to cause the 
emergence of more virulent strains or, which is even more important, cannot 
be used in immunocompromised individuals due to the risk of severe 
infection.  For example, the live attenuated seasonal influenza virus vaccine 
FluMist is recommended for individuals between 2 and 49 years old only, 
excluding the most vulnerable populations – infants and elderly (349, 350). 
Live bacteria and viruses can also be used as vaccine vectors carrying 
recombinantly expressed Ags from other pathogens. However, a problem 
with this strategy is the stimulation of vector-specific immunity that may 
reduce the immunogenicity of the engineered Ag and in this way lower the 
efficacy of the vaccine (351). The adenovirus vectors are examples of this 
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potential risk. 
Killed vaccines are safer, but less immunogenic and require an adjuvant to 
trigger strong immune responses. Vaccines against rabies, influenza and 
typhoid fever are all examples of killed vaccines. These vaccines are non-
infectious, and can be used broadly among populations, including 
immunocompromised individuals.  As they lack the endogenous activator of 
the innate immune response they require addition of an external adjuvant. 
These are most often PRRs such as lipid A, CpG or aluminum salts, but they 
can also be AS03, which was the adjuvant used in the Pandemrix influenza 
vaccine, that caused narcolepsy in some cases in Finland and Sweden (352, 
353).  Hence, adjuvants can be reactogenic and cause side effects and, 
therefore, safer and more stable vaccine adjuvants are needed.  
A form of killed vaccine is the subcomponent vaccine, which hosts only 
fragments of the infection and not the whole microorganism, and these are 
attractive candidates to replace live attenuated vaccine with. They could 
reduce vaccine production costs, ensure safety and provide more robust and 
stable vaccines. Such vaccines can consist of bacterial or viral proteins or 
fragments of the cell wall or the virus capsid. This provides many different 
options and a multitude of possible approaches to the design of a new 
vaccine. As aforementioned, subcomponent vaccines are weakly 
immunogenic and require incorporation of adjuvant. In this thesis we have 
worked with a subcomponent approach to design a novel HuNoV vaccine. 
We have focused on the potential of immunogenic peptides derived from 
HuNoV major protein VP1 and combined these into fusion proteins that carry 
endogenous adjuvant activity and developed a mucosal vaccine to be given 
intranasally (i.n.). The mucosal adjuvant we have explored is the CTA1-DD 
adjuvant platform that was developed in our laboratory to circumvent the 
toxic side effects of cholera toxin (CT).  
The Ag used in a vaccine should not only be an inducer of significant 
immune responses, but should also stimulate biologically relevant immune 
protection against the pathogen. We developed a strategy involving the 
selection of the best peptide candidates from the HuNoV capsid that could 
stimulate strong immune responses. B cell responses most often do not 
identify linear peptides but we identified that the MAbs we generated, indeed, 
could detect linear peptide epitopes. By contrast, T cells only react to linear 
peptide sequences, and screening for specific responses could be 
cumbersome and difficult, but instead in silico predictions using computer 
databases could be used to identify the affinity to MHC class I and/or II 
molecules that preferentially will bind the peptide. In silico predictions 
Inga Rimkutė 
 
43 
enable faster evaluation of peptide candidates and can also predict their 
fitness in humans by measuring the affinity between the peptide and the HLA 
subsets. In silico tools can also be consulted to identify well conserved amino 
acid sequences across the family of pathogens and localize them to the whole 
protein. The immunogenicity of peptides should be verified in vivo before 
incorporating them into the vaccine. The approach of this thesis has been to 
use the DD molecule to target binding sites on the APCs. This will ensure the 
delivery of the Ag to its target cells. The final processing of the vaccine Ag is 
coordinated by the cathepsin family enzymes inside the cell. Of note, 
susceptibility to protease degradation must be prevented before the antigen is 
taken up by APCs. Finally, the vaccine candidate can be tested in vivo, and 
immune responses can be advanced by challenge studies if available for a 
specific pathogen.  
3.3 MUCOSAL VACCINES 
A majority of all pathogens gain access to the human body through mucosal 
surfaces. Hence, mucosal vaccination leading to protective immunity at 
mucosal sites is much warranted. However, at present injectable vaccines 
dominate the market, but these vaccines most often fail to stimulate immune 
protection at mucosal sites. In contrast, mucosal vaccines can stimulate 
antigen-specific tissue resident cell-mediated immunity as well as local 
secretory IgA (sIgA), which is also accompanied by strong systemic IgG 
responses (354, 355). Therefore, mucosal vaccines may stimulate strong and 
long-lasting immune protection at both mucosal and systemic sites (356, 
357). Mucosal vaccines are also superior to   injectable vaccines for their 
lower production costs and stability, as well as for being safer, hosting better 
compliance and for their administration via the mucosal routes, not requiring 
medically trained personnel. They are considered excellent for mass 
vaccination, as they do not carry a high risk of spreading, for example, blood-
borne diseases. This can occur through the use of contaminated injection 
needles. Despite all these merits, few successful mucosal vaccines have been 
licensed. Among those are oral cholera, typhoid, polio and rotavirus, or 
intranasal influenza vaccines (358-360). It is crucial to consider the route of 
administration, the adjuvant to be used and which delivery system to employ 
in the next generation of mucosal vaccine (361). 
3.4 DELIVERY ROUTE 
The mucosal immune system displays a high degree of anatomical 
compartmentalization related to the migratory patterns of lymphocytes when 
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activated at different mucosal sites. The selective localization of mucosal 
lymphocytes to specific tissues is determined by “homing” or chemokine 
receptors. The anatomical organization of the mucosal immune response 
limits the choice of vaccine administration routes. This implies that whereas 
intranasal vaccinations provide good immunity in the respiratory tract they 
convey poor immunity in the GI tract. Vice versa, oral immunizations give 
better protection in the gut, while stimulating weaker immune protection in 
the lung. On the other hand, also intranasal immunization can provide gut 
protection as shown with HuNoV VLPs, which stimulated fecal IgA 
responses (362). Indeed, vaccines used intranasally with GI.1 VLPs were 
found to be protective against a GI.1 challenge infection (363).  
Oral and nasal routes are the most explored administration pathways for 
mucosal vaccination. Other mucosal delivery routes can be identified such as, 
rectal, vaginal or sublingual routes. All these routes have been shown to work 
well as assessed in the different experimental animal models (364). While 
most mucosal vaccines are administered orally, this route is considered the 
most challenging to succeed with. The reason is the harsh gastrointestinal 
environment, which degrades most Ag epitopes before they are delivered to 
the immune inductive site. Therefore, oral vaccines nearly always require 
higher doses of Ag and an effective mucosal adjuvant. Another reason for 
poor oral immunogenicity is the fact that protein antigens induce immune 
suppression or tolerance instead of protective immune responses when given 
orally.  Because of these shortcomings intranasal vaccines can be more 
attractive than oral vaccines due to the lower dose of Ag and adjuvant 
required (357, 363, 365-367). This also applies to sublingual vaccines, which 
are also gaining attention, because they can induce both mucosal and 
systemic B and T cell responses in the gastrointestinal, respiratory and genital 
tracts (364). This route also requires lower amount of antigen than the oral 
route. Finally, and in contrast to other mucosal routes, the sublingual route 
avoids activating cells in the central nervous system, as observed with some 
of the mucosal adjuvants, such as cholera toxin and E.coli heat-labile toxin in 
humans (368-370). 
3.5 ADJUVANT 
Immunizations with purified antigen alone are most often unable to induce a 
significant immune response. This is because the default pathway for 
mucosal immune responses to protein antigens is tolerance or immune 
suppression. To avoid tolerance, immunizations require co-administration of 
immunostimulatory agents called adjuvant (adiuvare translated from Latin 
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means to help). There are many different types of adjuvants, and these are 
often molecules, which act through PRRs on the innate antigen-presenting 
cells. Also, cytokines and bacterial toxins can exert adjuvant effects as they 
trigger activation and maturation of DCs resulting in efficient priming of 
CD4 T cells in the draining lymph nodes.  
PRRs recognize molecules typical for the pathogens and are important for 
activation of innate immunity. For example, toll-like receptor 2 (TLR2) is 
activated by bacterial lipoproteins from Mycobacterium tuberculosis, which 
is a key component of complete Freund’s adjuvant (CFA) (371). 
Furthermore, poly I:C mimic double stranded RNA and provides strong 
activation of the TLR3 pathway (372). This leads to IFN-α/β production 
resulting in TLR1, 2, 3 and 7 expression (373), DC activation (374) and 
priming of Th1 responses (375). Monophosphoryl lipid A (MPL), a 
detoxified derivative of lipopolysaccharide (LPS) from Salmonella minnesota 
R595, is an agonist of TLR4 and immunoenhances Th1 responses by 
triggering IL-12 and IFN-γ production (376). In fact, MPL is already used in 
some licensed vaccines, such as an anti-allergy vaccine (Pollinex Quattro®) 
(377) or a stage IV melanoma vaccine (Melacine®) (378). Moreover, TLR5 
is activated by flagellin, from bacterial flagella, resulting in TNFα 
production, which is associated with high antibody titers and a mixed 
Th1/Th2 response (379). Another adjuvant formulation is imidazoquinolines, 
which mimic single stranded RNA, which is recognized by TLR7/8. Whereas 
Imiquimod is activating only TLR7, resiquimod can activate both TLR7 and 
TLR8. Both substances stimulate IFN-α and IL-12 production (380), and 
activate CD8 T cells (381). Of note, resiquimod enhances B cell responses in 
both humans and mice (382). CpG is oligodeoxynucleotides (ODN) 
composed of unmethylated CG motifs (cytosine phosphate guanidine) and is 
recognized by TLR9. This leads to upregulation of costimulatory molecules 
(CD40, CD80, CD86) and proinflammatory cytokines (IL-6, IL-12, IL-18, 
TNFα) (383, 384). Mannose receptors (MRs) have been described to react to 
α-D-mannopyranosyl residues common on glycoproteins of parasites, 
bacteria, yeasts and enveloped viruses (385, 386). These receptors have also 
been shown to trigger cytokine secretion and DC activation (385, 387). 
Despite a broad variety of experimental adjuvants, only few are effective or 
safe enough to be exploited in current vaccines under development.  
Bacterial enterotoxins, such as cholera toxin (CT) or Escherichia coli heat 
labile toxin (LT) have been recognized as the golden standards for an 
effective mucosal vaccine adjuvant (388). They are AB protein complexes, 
where the A subunit is composed of the A1 and the A2 chains linked to the B 
pentamer subunits (CTB), i.e the CTB pentamer. The A1 portion hosts ADP-
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ribosyl transferase activity that stimulates increases in intracellular cAMP. 
By contrast, the CTB subunit binds to GM1 ganglioside receptors present on 
the cell membrane of all nucleated cells, including DCs. While CT has 
specificity only to GM1 ganglioside, the LT toxin could also bind additional 
gangliosides like GM2 (389, 390). Unfortunately, despite being the most 
potent mucosal adjuvants CT and LT carry toxic side effects, which preclude 
clinical use. Therefore, different approaches have been taken to overcome 
this issue. Most attempts have tried mutating the A1 enzyme while hoping to 
have retained adjuvant function. The CTA1-DD adjuvant is derived from CT 
holotoxin, as it carries the enzymatically active CTA1 subunit fused to a 
dimer of the D-fragment from Staphylococcus aureus protein A (DD). The 
CTA1-DD exerts comparable adjuvant effects to those of CT holotoxin and 
has been found effective and non-inflammatory in mice, guinea pigs and 
monkeys (391, 392). Also, as it lacks the B subunit it fails to bind the GM1 
ganglioside, which results in that it cannot accumulate in the central nervous 
system following intranasal administration and it remains safe after intranasal 
immunizations (393-395).  
Figure 9. Experimental adjuvants recognized by PRRs and gangliosides.  
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3.6 VACCINE FORMULATION 
The formulation of vaccines is another critical step in optimizing its’ 
immunogenicity. An ideal mucosal vaccine delivery formulation should 
protect from enzymatic degradation and induce an efficient uptake and 
presentation of Ags by DCs. Furthermore, the physicochemical qualities of 
the delivery system like particle size, surface charge and hydrophobicity 
should be adapted to allow the Ag to cross the mucosal membrane (396). 
Therefore, a number of diverse delivery systems for mucosal immunization 
have been developed including inert systems such as microparticles, 
nanoparticles, liposomes, immune stimulating complexes (ISCOMs), and 
different live attenuated bacterial or viral vector systems (361). 
Mucoadhesive components could help to overcome a constantly renewing 
mucus layer by facilitating contact between the vaccine formulation and the 
mucosal membrane. Examples of such molecules are chitosan and starch, and 
these prolong the vaccine retention time and increase the chance of effective 
Ag uptake. Other strategies to target the mucosal membrane and facilitate Ag 
uptake are based on particulate formulations including VLPs, bacterial 
ghosts, microparticles, nanoparticles, liposomes and ISCOMs. These 
formulations can also establish close contact with the mucosal epithelium 
through the inclusion of adhesive (lectins, MAbs) and/or immunomodulating 
(TLR ligands, CTB) molecules (397, 398). It is expected that the efforts 
invested into new formulations of mucosal vaccines will be successful and 
that we will see a growing number of licensed mucosal vaccines in the future.   
3.7 IMMUNITY AGAINST NOROVIRUS 
It is predicted that the future success of a novel HuNoV vaccine will heavily 
depend on its ability to stimulate long-lived protective immunity. Modeling 
studies have suggested that naturally induced immunity against NoV could 
last 4-9 years (399). However, human challenge studies failed to find 
immunity lasting longer than 2 years (range between 2 months and 2 years) 
after NoV inoculation even with inoculums significantly higher than would 
be observed in naturally acquired infections (310, 400, 401).  Currently no 
clinical data collected from challenge studies support that immunity against 
HuNoV of longer duration can be induced (402, 403).  However, this being 
said it should be emphasized that antigenic diversity of norovirus strains is 
known to undergo great variation. In fact, already the early human challenge 
studies with norovirus demonstrated that naturally acquired immunity against 
one strain would not necessarily protect against another strain (6). Therefore, 
the ideal vaccine formulation should stimulate immune protection against 
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conserved epitopes of the HuNoV, resulting in strong cross-reactive and 
long-lasting immunity against both present and emerging HuNoV strains.  
3.7.1 HUMORAL IMMUNITY 
Many studies have been conducted to analyze humoral immunity against 
HuNoV. Compared to T cell mediated immunity, antibodies against HuNoV 
are thought to last longer, but there may still be a lack of memory B cell 
development following a HuNoV infection (310, 404-406). Nevertheless, the 
importance of protective antibodies in serum has been correlated to a reduced 
infection rate and less severe gastroenteritis (86, 400, 407, 408). Also, 
immunocompromised individuals can develop chronic HuNoV infections 
clearly emphasizing the need of antibodies to resolve infection (67, 409, 
410). It is believed that protection against HuNoV is primarily mediated by 
neutralizing antibodies, but other mechanisms could be operational in 
protection. To this category we should count in antibody-dependent cellular 
cytotoxicity (ADCC), which has been shown to play a protective role against 
influenza infection (411, 412). A large number of studies have been 
published evaluating MAbs against HuNoV in different in vitro or in vivo 
assays. These have reported on a protective capacity when recognizing 
epitopes in the VP1 capsid protein (413). Further efforts are needed to 
understand the relationship between HuNoV diversity and host protective 
immunity, as well as the mechanisms used by the virus to evade the immune 
response.   
3.7.2 B CELL EPITOPES 
Genogroup specificity 
Blocking antibodies have been found to convey protection against clinical 
norovirus gastroenteritis (414). Hence, MAbs and nanobodies have been 
generated against different norovirus VLPs and used to define blocking 
epitopes on the capsid of norovirus. The blocking capacity of the different 
MAbs and nanobodies was evaluated using two different assays, the 
hemagglutination inhibition (HAI) and HBGA binding assays. Despite this, 
only very few antibody-blocking epitopes have been identified for the GI.1 
and GII.10 genotypes. Interestingly, most anti-GI.1 MAbs and nanobodies 
uniquely bind to the GI.1 genotype, which suggests sequence diversity across 
the genogroups reflecting differences in the P domain. This would also be 
important when considering antibody treatment in combined therapeutic 
interventions (415, 416). By contrast, the GII.4 genotype has 8 predicted 
antibody-blocked epitopes, A through H. Epitopes A through E were 
predicted based on sequence alignments and comparison of variable residues 
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across pandemic GII.4 sequences (417). Epitope A has shown 
immunodominance over the other GII.4 epitopes. Around 40% of serum 
antibodies have been found to block the epitope A (272, 417).  Interestingly, 
changes in epitope A have been found to correlate with the emergence of new 
virus strains of the GII.4 genotype. The A epitope is exposed in the P2 
domain and independent of the VLP conformation (272, 418). On the other 
hand no blocking MAbs have been mapped to the B epitope, which is hidden 
in the dimer between two VP1 monomers and could be important for residues 
located on the surface of the VLP. Epitope C is also located on the surface, 
directly proximal to the HBGA binding pocket, and has been associated with 
the strain-specific HBGA blockade (419). Epitope D faces the outer surface 
of the VLP in the P2 domain and does not change due to the NERK domain 
effect (420). This domain hosts the binding site for MAbs and is also close to 
the HBGA binding domain. Importantly, polymorphisms in the D epitope 
have been implicated in escape mutants from herd immunity and HBGA 
ligand switch (272, 421, 422).  It has been shown that changes in the D 
epitope can modify affinity for different HBGAs by stabilizing bonds with 
non-H (such as Lex and sialyl-Lex) antigen HBGAs (277, 423). Such 
information may give insights into virus adaptation to higher virulence and 
larger populations of susceptible people.  Epitope E is lateral to A and D, but 
is less exposed (421). It has a high variability among major GII.4 epidemic 
strains indicating that it is a critical site for the emergence of antigenically 
novel GII.4 strains (273, 421). Furthermore, Epitope E has been shown to be 
temperature sensitive (424). A similar temperature-dependent epitope is the F 
epitope, which is conserved among GII.4 strains. Interestingly, it has been 
observed that changes in Epitope F have affected binding of MAb to Epitope 
E (424), despite that these epitopes do not share amino acid residues. 
Epitopes G and H have not been characterized yet, but it is thought that 
Epitope G might be located close to Epitope F, and Epitope H might be 
influenced by Epitope A (420, 425). Of note, also less well described 
epitopes exist and are predicted to be important for virus pathogenicity and 
immunogenicity. Studies using nanobodies have identified that some 
nanobodies might be cross-reacting with 7 different GII genotypes and block 
GII.4 VLP binding to HBGAs (419). Most importantly, a nanobody has also 
been mapped to a linear epitope located on the P1 domain and another 
nanobody reacted only with GII.4 and GII.10 epitopes when the P particles 
were dimeric and not monomeric (426). Blocking epitopes mapped to GI.1, 
GII.4 and GII.10 P domains are depicted in Figure 10. 
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Figure 10. HBGA blockade epitopes mapped to (A) GI.1, (B) GII.4 and (C) GII.10 P domains. 
Golden color above the linear P domain presentation – HBGA binding residues; asterisk (*) – 
do not have an antibody/virus structure associated with their epitope definition. (413) 
Neutralizing epitopes 
Do MAbs against HuNoV host neutralizing properties? This was investigated 
in recent studies, but relatively few of these studies have been published 
(121). To date only one blocking and neutralizing anti-GII.4 MAb, 10E9, has 
been mapped to GII.4 P domain. The epitope of 10E9 overlapped with the 
HBGA binding pocket (Fig. 11)(427, 428). Interestingly, though, 10E9 MAb 
could neutralize GII.4 virus from patient stool samples, but it failed to block 
GII.4 NSW 2012 VLP binding to HBGAs (428).  
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Figure 11. MAb 10E9 relation to HBGA binding site in GII.4 P domain. Golden color – HBGA 
binding pocket (413).  
Linear B cell epitopes in norovirus 
Though a majority of B cell epitopes identified by MAbs has been 
conformational, some MAbs have recognized linear epitopes mapping to S 
and P1 domains of the GI and GII genogroups (413). Amino acid sequences 
spanning the S domain are more conserved than those in the P1 domain (420, 
424). These MAbs, mapping to linear epitopes, were found to be cross-
reactive and have been used in diagnostic assays. However, their protective 
capacity remains to be evaluated (429-431).  
3.7.3 VIRAL ESCAPE FROM BLOCKING 
ANTIBODIES 
There are two factors determining the blocking capacity of the specific 
MAbs. The first is the amino acid sequence of the MAb epitope and the 
second is whether antibodies can get access to the epitope, which partly may 
be influenced by the flexibility of the P domain. A majority of HBGA 
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blocking antibodies identify epitopes that are within or proximal to the 
HBGA binding site. Accordingly, the direct binding of MAbs to the HBGA 
site should prevent viral infection. However, this may not be the case should 
an antigenic drift affect the P domain, which would eliminate the blocking 
effect of the MAbs. But, interestingly, reports have indicated that amino acid 
changes close to, but not in, the binding pocket are the ones that most affect 
the blocking ability of the MAbs (272). This could result in the complete loss 
of MAb binding without any critical change in the actual HBGA binding 
pocket. Furthermore, amino acid changes can lead to conformational changes 
of the HBGA pocket. This could be yet another mechanism to prevent MAbs 
from binding to the epitope (424). During evolution the virus could adjust 
changes to the amino acid sequence around the HBGA binding pocket and in 
this way expand the pool of potentially susceptible people to infect (423). 
Moreover, the norovirus capsid has been shown to be flexible depending on 
the temperature, and conserved epitopes, buried within the VLP at room 
temperature, can become exposed at 37°C (420). This feature might be 
particularly important for virus transmission (420). The “viral breathing” 
dependent on temperature is determined by the motif of amino acid residues 
called NERK (amino acids 310, 316, 484 and 493). Together these amino 
acids might comprise a proposed viral “breathing core” and regulate epitope 
presentation and ligand binding to the P domain (424). This notion suggests 
that exposure to changes in body temperatures might influence the binding 
efficiency of specific antibodies and, therefore, it should be considered when 
interpreting results from in vitro experiments. Interestingly, these temperature 
camouflaged epitopes could be particularly important targets for 
interventions based on MAb recognition.  
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Figure 12. Mechanisms of MAb mediated blockade to HBGA binding pocket and viral immune 
escape strategies (413). 
3.7.4 CELLULAR IMMUNITY 
Human norovirus infection leads to recruitment of monocytes to the infected 
tissue and the production of cytokines, in particular IFN-γ, IL-2 and TNF-α	(81,	 432-435). Elevated levels of these cytokines were detected in human 
serum and stools within a few days in the course of infection. Concomitantly 
it was observed that Th1 and cytotoxic CD8+ T cell immunity were 
upregulated (415, 432, 436, 437). The detection of high levels of IL-10 at 3 
days into the infection might reflect a down-modulation of the immune 
response, but this must be more thoroughly investigated (432, 436). Also IL-
4, IL-5, IL-6 and IL-8 could be detected already after a few days into the 
infection (435, 436, 438) and these might represent Th2 and Tfh cell activity, 
which is critical for the B cell response. Whereas a majority of these findings 
have been made with peripheral blood cells further studies are needed to 
investigate local immune responses in the intestine, at the site of infection.  
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While no animal model exists for studies of HuNoV there are excellent 
models of murine NoV (MuNoV), which allow for detailed studies of 
protective immunity and viral pathogenesis.  For example, MuNoV has been 
found to be endocytosed through the M cells that overlay the Peyer’s patches 
(PPs) in the small intestine. The MuNoV is then transported into the PPs and 
can get access to cells also in the mesenteric lymph nodes (MLN). Thus, the 
MuNoV may infect the host cells differently and with a different tropism than 
that of HuNoV (439, 440). The MuNoV is also known to infect macrophages, 
DCs, B and T cells in the PPs (99, 102, 122, 439). Infected cells release type 
I IFNs, which initiate innate immune responses and play a key role in 
limiting MuNoV replication (441-443). Adaptive immunity against MuNoV 
is dominated by activated CD4 and CD8 T cells, as well as antibody 
producing plasma cells (335, 444). Indeed, specific CD4 T cells correlated 
with protection after re-exposure to MuNoV in mice (445). Nevertheless, it 
remains difficult to extrapolate findings in the mouse model to humans 
directly.  
3.7.5 T CELL EPITOPE MAPPING 
The diversity of HuNoV strains makes the identification of cross-reactive T 
cell epitopes difficult. Few challenge studies with the GI.1 or GII.2 norovirus 
genotypes have found cross-reactive T cells or IFN-γ responses to 
heterologous VLPs (415, 435). Another study identified varying T cell 
activation levels over the course of infection (436). Interestingly, gnotobiotic 
pigs immunized with human P particles intranasally or orally demonstrated 
activation of CD4 T cells in the intestinal and systemic secondary lymphoid 
tissues, and CD8 T cells in the duodenum (90). On the other hand, the same 
study found P particles to elicit weaker heterogeneous protection than VLPs, 
suggesting that the S domain is of importance for cross-reactivity. To date 
there have been only a few T cell epitopes identified for HuNoV (Fig. 13). 
Most of them were identified by stimulating peripheral blood T cells from 
VLP-immunized individuals, which were reported conserved epitopes shared 
by GI and GII strains (446, 447).  Another example is the study that was 
conducted in mice and which identified T cell epitopes spanning the VP1 
region of human GII.4-1999 strain, GII.4 genotype, or even genogroup GII 
(448). The peptides were restricted to either CD4 or CD8 T cell recognition. 
It should be emphasized that the results of the latter study disagree with 
earlier findings reported by Dr. R. Baric group (447). Whereas, both groups 
identified the same peptide in recall experiments it was claimed that one was 
reactive to CD4 T cells while the other one was reported as a CD8 T cell 
epitope. This discrepancy might be due to different mouse models, 
immunization routes or even reagents used for the studies. Another study 
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reported a human CD8 T cell epitope, which was cross-reactive in four 
patients of the same HLA-A(*)0201 (449). The 10 amino acid long peptide 
belongs to the S domain and is highly conserved across GI and GII 
genotypes, but not found in the GII.4 Sydney strain.  Additional studies are 
needed to get a better picture of how specific CD4 and CD8 T cells can 
convey protective immunity and their location and dynamics in the affected 
tissues. Also, studies of the earlier history of exposure to HuNoV infection 
and individual HLA patterns in different age groups could contribute to a 
better understanding of how protection against HuNoV infections works. 
Overall, it remains of high importance to identify dominant T cell epitopes 
that are conserved among different strains of HuNoV in human. 
Figure 13. Identified T cell epitopes and their mapping to the VP1. Grey – MuNoV specific 
epitopes; red – GI – specific epitopes; blue – GII – specific epitopes; bolded peptides and 
yellow in 3D model – cross-genotype reactive epitopes. The 3D structure is of GI.1 VP1 (413).  
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3.8 COMPETING VACCINE STRATEGIES 
While several norovirus vaccine candidates are under development or are 
being evaluated in clinical trials there is still a need to concentrate on 
preclinical investigations of HuNoV vaccine candidates. Two groups are 
developing VLP-based vaccines, where one vaccine contains GI.1 and GII.4 
VLPs and is presently in Phase 2b clinical trials (Takeda), and another 
vaccine contains GI.3 and GII.4 VLPs and remains in preclinical studies. 
Two other groups have developed vaccines based on recombinant adenovirus 
serotype 5 vectors expressing norovirus VP1. One is based on a GI.1 
norovirus sequence and is in a Phase 1 clinical trial (Vaxart), while the other 
is based on a GII.4 sequence and is undergoing preclinical studies. A fifth 
group has published extensive preclinical data on a GII.4 P particle-based 
vaccine (450). The Takeda bivalent vaccine is administered intramuscularly 
and contains adjuvants aluminum hydroxide and MPL.  Though this vaccine 
induces specific serum antibody responses, increases HBGA-blockade 
antibody levels, stimulates plasmablast responses and memory B cells against 
norovirus vaccine strains, it has failed to demonstrated long-lasting protective 
immunity (145, 146, 451, 452). This is an essential aim for a mucosal vaccine 
against HuNoV. While intramuscular administration of the vaccine has poor 
chances to induce effective mucosal immune responses, the Vaxart vaccine 
was developed as a tablet for oral delivery. Lately its’ safety and 
immunogenicity were confirmed in a Phase 1 clinical trial. This study 
showed norovirus-specific IgA antibodies in feces for up to 6 months 
following immunization (144). Further studies are awaited to confirm the 
efficacy of this vaccine. Noteworthy, the use of an adenovirus vector as a 
delivery system could potentially lower the vaccine efficacy as pre-existing 
adenovirus-specific antibodies could reduce the amount of vaccine Ag 
available following vaccination (351).  
We have chosen to develop a novel mucosal subcomponent vaccine based on 
the inherent adjuvanticity of the CTA1-DD platform and selected peptides 
from the virus capsid.  We have then explored the potential of our mucosal 
vaccine candidates by assessing the immunogenicity of the T and B cell 
epitopes and the ability to recognize the selected peptides by specific MAbs 
or serum antibodies from infected people.  To this end we choose 15-mer 
peptides for determining binding sites for antibodies against epitopes of the 
Dijon strain. The identified B and T cell epitopes were selected on the basis 
of to providing strong cross-protective immunity resulting in better viral 
clearance, enhanced memory responses and increased protection against 
reinfection. 
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4 AIMS 
To advance our current knowledge on the pathogenesis and prevention of 
gastrointestinal NoV infections this thesis has focused on two crucial issues. 
The first was to identify membrane elements that are required for HuNoV 
infection, specifically in epithelial cells of human intestinal enteroid cultures. 
The second was to identify highly immunogenic peptides from the human 
norovirus capsid for generating a subcomponent vaccine that stimulates 
strong virus-specific immune responses. Therefore, we focused on two 
challenges that are discussed along the thesis: 
1. To characterize the membrane components of human gastrointestinal 
cells allowing for NoV infection.  
2. To test the viability of a novel way to design a mucosal NoV 
subcomponent vaccine by employing information on VLP-specific 
monoclonal antibodies and their binding patterns to the capsid of the 
virus. 
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5 METHODOLOGICAL ASPECTS 
This is an overview of the main methods used in this thesis work. A detailed 
description of each method can be found in the individual papers. Since, the 
work plan addressed two different fields of research, namely glycobiology 
and immunology, this is also reflected in the methods used.  
Virus-like particles (VLPs) 
It has been shown that VLPs preserve binding and antigenicity features of the 
native virus (312). Thus, we employed VLPs of different strains to study 
virus-glycan binding and virus immunogenicity. Paper I used norovirus GII.4 
004/95M VLP (GenBank access number: AF080551.1), which was His-
tagged to enable direct measurements of the VLP-glycan interactions. The 
polyhistidine tag was added at the C terminal of the VP1 and is described 
elsewhere (453). Paper II has used GII.4 Sydney VLP (GenBank access 
number: AFV08795.1), which represents the latest strain of known globally 
spread GII.4 genotypes.  In Paper IV we used GII.4 Dijon VLPs (GenBank 
access number: AAL79839.1) to immunize mice and develop MAbs against 
this strain. We used the sequence of the GII.4 Dijon capsid to generate a 
peptide array to identify distinct peptides that the MAbs reacted with. All 
VLPs were produced in insect cells using the well-established baculovirus 
expression system (454). Since each VLP was made in a different laboratory 
minor differences exist in their protocols. For example, GII.4 004/95M and 
GII.4 Dijon VLPs are assembled of the VP1 capsid part only (455, 456), 
while the GII.4 Sydney VLP is a result of the VP1 and VP2 expression (457). 
Though the VP2 is important for the stability of the virion, but how it 
influences the whole VLP is less well understood. Nevertheless, we used 
GII.4 VLPs due to their higher prevalence in norovirus caused outbreaks.  
Human intestinal enteroids (HIEs) 
Human norovirus pathogenicity studies have been delayed for a long time 
due to the lack of study models. Just recently it became possible to replicate 
the virus in laboratory settings in stem cell derived HIEs. The stem cells are 
isolated from intestinal crypts obtained from human intestinal surgery or 
biopsy samples. These cultures retain the genetic and biologic properties of 
the donors, which can lead to the discovery of host-specific factors that affect 
susceptibility to infection and result in personalized approaches to treat 
individuals. HIEs recapitulate the natural intestinal epithelium and are non-
transformed, physiologically active cultures that can be maintained endlessly. 
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They produce self-organizing structures that contain the multiple 
differentiated intestinal epithelial cell types including enterocytes, goblet 
cells, enteroendocrine cells and Paneth cells. Since HIEs recapitulate the 
HBGA phenotype of the donor genotype, they are an excellent model to 
extend our understanding of how host HBGA and HuNoV interact and which 
specific requirements are needed to allow infection. In this thesis we 
analyzed the glycoconjugate and lipid composition of HIEs recapitulating the 
small intestine of 6 individuals of different HBGA status.  
Glycosphingolipids 
The reference GSLs used in Paper I, II and IV were purified and 
characterized as previously described (458-462). The type 1 chain GSLs were 
isolated from human meconium samples of either a single individual or 
individuals pooled according to their ABO blood group phenotype. The type 
2 chain structures were purified from canine small intestine. The glycolipid 
extracts from an adult human intestinal epithelium were a gift from Prof. 
Michael Breimer and the GalCer and GlcCer references were a gift from 
Assoc. Prof. Niclas Karlsson.   
Folch partitioning 
The Folch partitioning method was introduced in 1957 (463). It describes a 
now classical procedure, which allows extraction of lipids from a tissue and 
separation of lipids based on their polarity into two phases, the lower phase 
and the upper phase, respectively. The lower phase containing non-polar 
lipids collects all the lipids, including sphingolipids with shorter glycan 
chains from a tissue, while the upper more polar phase contains 
glycosphingolipids with longer glycan chains, gangliosides and salts. 
Importantly, the highly polar glycolipids can be separated from other lipids 
by Folchs’ partition and the denaturated proteins are found mainly in the disc 
in-between the two phases. Neutral glycolipids with 5-7 monosaccharides are 
found in both the lower and the upper phases, and the clear-cut between them 
is dependent on each glycolipid structure but also on the coexisting 
phospholipids, other lipids and the concentration of ions present in the lipid 
extract. It has been observed that if the method is applied to human 
erythrocyte glycolipids, the upper phase contains 90% of the GSL with more 
than 5 glycan residues and higher gangliosides, while the lower phase 
contains 90% of GSL with less than four carbohydrates residues (464). 
Furthermore, both phases can be used for further purification of sphingolipids 
and glycosphingolipids. For example, alkaline hydrolysis of the lower phase 
degrades all the phospholipids leaving the sphingolipid part of the sample. In 
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turn, the upper phase can, after a desalting step, also be used for further 
purification and characterization of glycosphingolipids and gangliosides. 
Overall, Folch partitioning is a very simple and efficient method to extract 
lipids from a tissue or cell line of interest. We used Folch partitioning in 
Paper II to characterize lipids and sphingolipids from HIEs. 
Thin-layer chromatography (TLC)  
TLC involves a stationary phase, which is a layer of particles of relatively 
uniform size (usually silica, alumina or cellulose) stuck onto a backing plate 
made of glass or metal. A complex mixture is applied on the plate as a spot or 
a band, is dried and the chromatogram is then developed in a suitable solvent, 
allowing the sample constituents to travel with different speed across the 
plate relating to the chemical and physical properties of the constituents 
present in the sample. Components of the sample have different preferences 
for the stationary and mobile phase. For instance, the sample mixture would 
separate according to the polarity of the solvents used over a silica coating. 
Subsequently the analytes are detected and identified based on their relative 
migration distance and based on their color reaction to chromogenic spray 
reagents ability to absorb light. For example, anisaldehyde stain is excellent 
for carbohydrate detection, while resorcinol is specific to visualize sialic acid 
containing structures. TLC may be used for both qualitative measurements as 
well as for semi/quantitative purposes. Since it is a fast, easy to handle and 
inexpensive procedure, it is one of the most widely used chromatography 
techniques. TLC was used to visualize extracted lipids from lower and upper 
phases from HIEs in Paper II.  
Chromatogram binding assay (CBA) 
CBA is a now classical method to study protein-GSL interactions. After 
developing a TLC of GSLs, the plate is coated with plastic and overlayed 
with the glycan binding protein of interest. The plastic coating protects the 
silica gel from detachment and covers the surface with a hydrophobic film, 
which improves the presentation of hydrophilic oligosaccharides (465). 
Though the method was originally established to study interactions between 
cholera toxin and gangliosides (466), it soon became extensively applicable 
for studies of other glycans binding proteins, including mono- and polyclonal 
antibodies, lectins, bacterial adhesins and viruses such as norovirus (292, 
306), parvovirus B19 (467, 468) and other (465). The CBA method was 
thoroughly used in Paper II to phenotype the lipid extracts from HIEs using 
HBGA recognizing antibodies and to study the binding of GII.4 Sydney VLP 
to pure glycolipids.  
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Total internal reflection fluorescent microscopy (TIRFM) 
Many studies have raised discussions about the nature of glycan-protein 
interactions and claimed that a static picture of glycan recognition might 
ignore differences in the presentation of the glycan epitope when compared to 
membrane bound glycans. The classical binding assays fail to encounter the 
complexity of glycan-protein interactions, including the fluidity of the 
membrane together with the potential lateral diffusion of membrane proteins 
and GSLs in the context of lipid rafts. Thus, studies of the role of specific 
glycoproteins or GSLs in viral entry require membrane-based assays. Indeed, 
such assays can unravel multiple questions regarding the very early steps of 
viral binding to cellular membranes, and also be applied as a screening 
method to identify viral receptors or attachment factors. TIRFM serves as an 
excellent platform to resolve both aspects (469).   
TIRFM was first introduced in 1956 (470) and since then it has been 
extensively used to study the properties of events at cellular membranes (471) 
and of transmembrane biomolecules (472, 473). The specific feature of 
TIRFM is that it uses evanescent waves to selectively illuminate the region 
just above the glass surface, with zero background from fluorescence in the 
solution above. When an incident beam of light is projected at the glass-
aqueous interface of the sample at an incident angle larger than the critical 
angle, it will be totally internally reflected. This leaves the electromagnetic 
evanescent waves on the surface of the glass, which exponentially decays as a 
function of perpendicular distance from the interface. Evanescent field 
penetration depths of <100nm can be readily achieved from total internal 
reflection at glass-aqueous interfaces, providing an opportunity to selectively 
excite fluorophores close to the interface. This allows a 5-10 fold advantage 
over the optical resolution achievable with confocal microscopy (≈ 500 nm). 
The technique consumes low amounts of material and is highly sensitive. It 
has the potential to detect association and dissociation events of vesicles 
binding to a single VLP on a lipid membrane. Furthermore, the setup is rather 
simple and the readout is rich in quantitative kinetics data, including analysis 
of different VLP-gycan interactions based on their binding strength and the 
real-time kinetics behavior of the GSL population over different durations of 
residence times.  Most importantly, TIRFM may be of great use for 
optimization in drug design where the effect of inhibitors on either the VLP-
vesicle or the VLP-glycan kinetics data might be important for choosing the 
most interesting candidates.  
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In this thesis, the TIRFM technique was exploited through different strategies 
in Papers I, II and IV, where protocols are described in greater detail.  
Lipidomics 
Lipidomics is a newly emerged analysis studying cellular lipids on a global 
scale based on analytical chemistry principles and novel technological tools, 
particularly mass spectrometry (MS). The discipline emerged in 2003 and has 
largely advanced due to the development of MS. A typical workflow for 
lipidomic analysis of biological samples starts with sample preparation, is 
followed by chromatographic separation and mass spectrometry-based 
analysis and is completed with data processing. Biological lipid extracts are 
typically complex, including the diversity of lipid 
classes/subclasses/molecular species and the vast dynamic range in the 
endogenous contents and concentrations of individual species. In order to 
reduce the complexity of lipid extracts and to improve the identification and 
quantification of individual species in the complex extracts, it is 
recommended to use liquid chromatography (LC)-based lipidomics. In 
addition, it allows the enrichment of the low abundance species. Overall, the 
LC-MS lipidomics identify lipid species from both chromatogram and mass 
spectral data, which adds valuable features to the species identification (474). 
The final output is qualitative and quantitative lipidomics data, which allow 
to characterize and to explore underlying mechanisms of lipid content and 
metabolism in health and disease, leading to applications in biomedical 
sciences, including the discovery of biomarkers, drug targets and guidance in 
precision medicine. The lipidomics work in Paper II was led by Assoc. Prof. 
Marcus Ståhlman at the Lipidomics Core Facility, University of Gothenburg.  
Glycoproteomics 
Glycoproteomics is used to identify and characterize proteins containing 
glycans and includes the identification of glycoproteins, elucidation of 
glycosylation sites and the structural analysis of glycans at each site of the 
glycoproteins. Since neither the proteome nor the transcriptome can 
accurately predict such a complex target, the glycoproteome must be 
analyzed unbiased, whether on a single glycoprotein or in a complex mixture 
of glycoproteins.  Analysis of the complete set of glycoproteins from a 
biological sample, including their glycan structures and sites of attachment, is 
primarily dependent on the analysis of (often tryptic) glycopeptides, which 
combine physical and chemical characteristics of both peptides and glycans. 
Thus, in a reversed phase LC-MS/MS set up the glycopeptides often migrate 
in close proximity to their corresponding un-glycosylated peptides and also 
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fragment in MS2 at peptide bonds giving typical B- and Y- ions identifying 
the glycoprotein sequence carrying the glycan attachment site.  Similarly, by 
using different fragmentation techniques and energies the glycopeptide parent 
ions will fragment their glycan parts at glycosidic bonds giving rise to 
diagnostic oxonium ions of released saccharides and sequence ions of the 
partially fragmented glycopeptides.  
Glycomics 
Different approaches and techniques are used to characterize released N-
linked and O-linked glycans of soluble or membrane bound glycoproteins or 
released sulfated GAGs of proteoglycans.  
In the case of the soluble glycoproteins, the N-glycans can be released 
enzymatically or chemically, separated by high performance liquid 
chromatography (HPLC) and sequenced by MS with or without further 
glycosidase treatments. The analysis of O-linked glycans would follow the 
same procedure, but has one important drawback that there is no single 
enzyme, which can release the O-linked glycans in general, which 
complicates the analysis of often large and complex O-glycoproteins. Thus 
chemical means are used for hydrolysis of O-linked glycans being bound to 
proteins or to ceramides.  Moreover, MS of glycans has challenges to 
determine the isomeric nature of the constituent monosaccharide units, 
linkage configurations and positions. Since different structures can have the 
same mass, often co-elute in separation systems and fragment similarly 
(although not identically) in MS/MS analysis, it is also challenging to assign 
a full structural analysis of glycans with only one method. It is therefore 
recommended to deliver glycan structures as possible assignments from one 
technology and to confirm them by at least one additional technology. There 
is an increasing amount of bioinformatics tools and databases becoming 
available to handle all structural data obtained from proteomic, 
glycoproteomics and glycomic analyses but mass spectral analysis is still 
heavily dependent on the expert manual interpretation. Paper III includes an 
extensive analysis of glycoproteins found in HIEs, the interpretation of which 
was conducted mainly by Assoc. Prof Jonas Nilsson.  
Monoclonal antibodies (MAbs) 
While the immune response to an antigen is usually polyclonal in nature, in 
1975 Köhler and Milstein were the first to describe the in vitro production of 
murine MAbs from hybridomas (475). Later technologies allowed to develop 
engineered human MAb on the basis of information gained from studies with 
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murine hybridomas. Today many functions of MAb technology are used. 
These include Fc region engineering, conjugation of drug to the MAbs, tissue 
targeting, and bispecific MAbs that can bind two independent epitopes. The 
in vitro phage display technology enables the generation of fully human 
compatible MAbs. While there is lack of information on whether the phage 
display generated MAbs behave differently in the clinical setting, this 
possibility has to be considered. Therefore, as a complementary technology 
to the classical hybridoma method phage display approached are highly 
attractive. MAb technology has had major impact on clinical treatments and 
they can serve as essential tools for diagnosis or therapeutic interventions. 
Also, MAbs are used heavily in pre-clinical research to identify immunogenic 
sites, epitope mapping, antigen detection, and in various neutralization 
assays. Moreover, MAbs can be used for gene cloning, protein purification, 
identification of cell surface markers, and analysis of different cell functions. 
They are also widely used in a number of immunoassays, for example for 
particle agglutination, radioimmunoassays, enzyme-linked immunosorbent 
assays, immunofluorescent antibody assays and immunohistology. Clearly, 
without MAbs-technology modern medicine would not be what is today. In 
current work we developed specific MAbs against HuNoV VLPs as 
presented in Paper IV.  
Enzyme-linked immunosorbent assay (ELISA) 
Since its’ invention in 1971 by two Swedish scientists Eva Engvall and Peter 
Perlman (476), ELISA has offered a wide palate of possibilities used 
primarily for detection of specific proteins or antibodies against the specific 
proteins. Indeed, ELISA is considered to be a routine method in both clinical 
diagnostic practice and in experimental systems. The ELISA method 
provides quick and accurate determinations, is highly sensitive, and relatively 
simple to perform. The technology can easily be automated and it is 
convenient for a large number of applications. In our study presented in Paper 
IV, ELISA was used to identify MAb binding to peptides relevant to HuNoV 
infections. 
Peptide array 
Peptide arrays are powerful tools for investigation of protein-protein 
interactions. In contrast to classical epitope characterization methods like X-
ray crystallography or multidimensional NMR, peptide arrays allow a large-
scale epitope identification, and evaluation of possible cross-reactivities in 
defined MAbs. This technology provides detailed epitope information on 
virus binding MAbs. Peptide arrays can be synthesized on solid phase 
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surfaces, which simplifies handling of large numbers of peptides or MAbs, 
and can eliminate the need for identification of peptides by de-novo 
sequencing. Epitope mapping is used for screening of biologically active sites 
in any given protein. The peptide sequences are generated by shifting a frame 
with a distinct peptide length over a protein sequence. The smaller the shift of 
the frame, the more precise will be the localization of the binding region. 
Thus, in Paper IV we screened for MAb-reactivity to epitopes on the HuNoV 
capsid, and the anti-norovirus MAbs were tested for binding to 526 norovirus 
peptides of 15-mers and 14 amino acids overlap. 
Immunizations 
To stimulate antibody production in vivo, we immunized Balb/c mice through 
the classical peritoneal route. Next we isolated splenic lymphocytes for the in 
vitro production of MAbs. We extracted activated B cells from the spleen, 
and fused these with hybridoma cells in hypoxanthine-aminopterin-thymidine 
(HAT)-discriminating medium.  
For mucosal immune responses we employed intranasal immunizations and 
evaluated the success by assessing antigen-specific T cell responses to recall 
antigen in vitro after isolating lymphocytes from the draining mediastinal 
lymph nodes (mLN). Additional analysis of antibody responses was carried 
out by ELISA, while thymidine incorporation was used for determining T 
cell proliferation and enzyme-linked immunospot assay (ELISPOT) was used 
for assessing cytokine production from antigen-specific T cells in the 
immunized mice.  
Assays to measure T cell immune responses 
We used H3-labeled thymidine incorporation and IFN-γ ELISPOT to measure 
T cell responses. Thymidine is incorporated into the replicating DNA of 
cultured cells, which results in a quantitative measure of the rate of DNA 
synthesis. This rate is proportional to the rate of cell division and, hence, 
reflects T cell responses to a certain antigen. The ELISPOT method is 
quantitative for assessing cytokine secreting effector T cells. It is a sensitive 
method for detection of single T cell responses. Both methods are conducted 
in vitro and are technically simple, easy to perform, require small numbers of 
cells and reagents. The combination of data from these assays is used to more 
precisely validate the findings that we obtain. 
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In silico studies  
Lately there has been a growing availability and refinement of computational 
resources and access to algorithms that can be applied for gaining better 
insights into the complex field of structure-and-function relationships 
between proteins. For instance, in silico methods can be used alone or in 
combination with experimental techniques for molecular-level understanding 
and protein engineering in drug design (477). The evolution of machine 
learning techniques has resulted in the development of large databases that 
can be exploited for different predictions of protein conformation, binding 
affinities and modes of ligands (dominant placement, conformation, 
orientation) bound to large protein complexes. Combinations of prediction 
tools can be applied to create solutions for problems in such areas as the 
design of vaccine compounds, drug-like molecules, or the discovery of novel 
materials. In Paper IV of this thesis in silico databases were consulted to 
optimize the design of the novel mucosal HuNoV vaccine formulation that 
we have developed.  
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6 KEY FINDINGS AND DISCUSSION 
In late 2015, at the time when this PhD project was started, there was no 
efficient cell culture system available to study HuNoV in laboratory settings. 
The majority of experimental norovirus studies relied on HuNoV VLP and 
MuNoV models. The accumulated evidence from challenge studies and 
binding experiments was pointing to the importance of the HBGAs in single 
individual’s susceptibility to the infection and norovirus VLP 
binding/attachment. Guided by the idea to explore the possibilities to design a 
novel mucosal vaccine against norovirus, we raised monoclonal antibodies 
against one of the HuNoV GII.4 genotype strains and conducted HBGA 
blocking experiments in a TIRF microscopy setting allowing for antigen 
presentation on a membrane model (Paper IV).  However, testing of 
immunogenic compounds against norovirus was limited to only 
immunizations due to lack of an animal model to study HuNoV infection. 
Finally, the human norovirus field attained a revolutionary discovery from 
the group led by Dr. Mary K. Estes when they published that HuNoV can 
indeed be replicated in human intestinal enteroid cultures (121). This finding 
was a breakthrough and spurred us to initiate Paper II and Paper III, which 
could contribute to the receptor/attachment factor research and future model 
studies in the field. Furthermore, we introduced an advanced study of VLP-
HBGA binding on the membrane model, where VLP binding could be traced 
directly (Paper I) and could have crucial implications for the studies of virus-
host interactions.   
6.1 PAPER I. NOROVIRUS VLPS FORM 
CLUSTERS UPON BINDING TO 
GLYCOSPHINGOLIPIDS 
The main concept of this paper using current biomembrane physical 
chemistry is studies of the formation of lipid rafts and their interaction with 
viruses or biologically relevant nanoparticles. This paper specifically 
explores the interactions employing his-tagged VLPs of a HuNoV GII.4 
strain and reference GSLs, H type 1 chain pentaglycosylceramide (H-1) and 
B type 1 chain hexaglycosylceramide (B-1), presented in supported lipid 
bilayers. Importantly, the paper is the first attempt to measure norovirus VLP 
binding dynamics directly on the membrane surface with post-binding 
labeled VLPs, thus, indicating that the binding of viruses or nanoparticles 
may induce deformations of the lipid bilayer. This advancement introduces 
measurements of events during and after VLP binding to the 
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receptor/attachment factors on the supported lipid bilayer, also providing a 
niche for future inhibition studies.    
The binding affinity of the VLP to supported lipid bilayer hosting a range of 
GSL concentrations was compared using QCM-D to measure the 
corresponding binding kinetics. It was evident that the binding rate of VLP to 
GSLs was dependent on the concentration of the attachment factor on the 
surface.  However, to achieve a firm attachment the VLP required at least 3 
times lower concentrations of the B-1 antigen than of the H-1. This finding 
points out a difference in the VLP binding affinity towards different GSLs in 
the supported lipid bilayer, where the affinity to B-1 was higher than that to 
H-1. The affinity of the receptor/attachment factors might play an important 
role in the virus uptake mechanism. 
The major difference observed upon the post-binding labeled VLP in binding 
to B-1 or H-1 antigens using TIRFM, was the heterogeneous versus the 
homogenous distribution of the fluorescent emission, respectively. The 
heterogeneous distribution appeared to originate from discrete objects of 
heterogeneous signal intensity and spatial extension, and was reproduced 
with both increasing concentrations of either the B-1 antigen or of the VLP. 
Importantly, there was no VLP aggregation in solution. In fact, if the 
aggregation in solution was the reason for the appearance of 
aggregates/clusters, it would have been observed irrespectively of the GSL 
type on the supported lipid bilayer. In addition, we could conclude that the 
size of aggregates/clusters was at least 3 times larger when the VLP was 
bound to the B-1 antigen-presenting surface. Furthermore, employment of 
pre-labeled VLPs revealed an increasing number of discrete objects as well as 
increasing intensity of the signal from these clusters over the time period 
studied. This could be explained either by the newly arriving VLP particles 
preferentially binding to the already bound particles or by the clustering of 
the laterally bound particles. Indeed, the latter explanation could be applied 
based on TIRFM time movies, but was difficult to analyze due to weak 
signals of single particles and the dye photobleaching effect on the signal. 
However, we could exclude the theoretical GSL-cluster formation by using a 
fucose-binding lectin, a competitor to the VLP for binding to the GSLs. After 
lectin addition, the VLP clusters became mobile. Taken together these 
observations lead to the speculation that the observed clusters are related to 
the interactions between the GSL in the supported lipid bilayer and the VLPs, 
which is supported by a more pronounced formation of clusters in the B-1 
antigen presence where the ligand-receptor/attachment factor interaction is 
stronger. Thus, the formation of a greater number of bonds between the VLP 
and the B-1 antigen appears more favorable. Indeed, despite the weaker 
Inga Rimkutė 
 
69 
energy of the individual interactions, the multivalent interactions could 
compensate and be strong enough to induce the deformation of the lipid 
bilayer locally at the binding sites. As a result, the VLP is partially wrapped 
or enveloped by the supported lipid bilayer. Importantly, these findings might 
reflect membrane-deformation-induced virus clustering on cell membranes 
and might function as signaling intermediates or low-energy transition states 
between the bound and internalized states in vivo. Similar membrane 
invaginations were previously reported on giant unilamellar vesicles with 
GII.4 Dijon VLP (296). Overall, Paper I emphasizes that the affinity of 
norovirus VLP/virus to the receptor/attachment factors most likely plays a 
critical role in viral endocytosis. Hence, this should be exploited in more 
detail in future studies of GSLs-interactions with the virus. Especially, 
studies of virus strains with significantly different binding affinities, coupled 
with labeling strategies capable of resolving structural changes at the 
molecular scale are highly warranted.  
6.2 PAPERS II AND III. GLOBAL ANALYSIS OF 
LIPIDS, SPHINGOLIPIDS AND 
GLYCOPROTEINS FROM HUMAN 
INTESTINAL ENTEROIDS SUSCEPTIBLE 
OR RESISTANT TO HUMAN NOROVIRUS 
The introduction of an infection model of HuNoV in HIEs has allowed for 
detailed studies aimed at revealing the virus-host interactions at the molecular 
level. This is an essential step towards the development of a human norovirus 
vaccine. HIEs provide a simplified model of human intestinal epithelium to 
study host-pathogen relationships in vitro and to mimic the pathobiology in 
the human gut. The importance of HBGAs in norovirus infection and binding 
has been extensively discussed earlier. The conceptual idea behind Papers II 
and III was to structurally characterize membrane components and HBGA 
epitopes on glycosphingolipids (Paper II) and glycoproteins (Paper III) from 
7 different HIEs, relating the HBGA glycans to the host geno- and 
phenotypes, and to correlate these observations with the known infectious 
susceptibility of these cell cultures.  
The major lipid components from all the HIEs were essentially identical and 
in the same quantitative ranges (Paper II). This finding is important not only 
as a support to the biological relevance of the HIEs model system, but also 
for the knowledge of complex lipid composition of differentiated adult 
intestinal cells, which can be applied in future studies of host-pathogen 
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interactions, drug delivery, or membrane models with a long-term goal to 
develop preventive and therapeutic treatments. However, important to note is 
that the general composition presented in Paper II does not address 
compositional asymmetries that apply over basolateral or apical parts of the 
membranes, nor does it differentiate between lipids from the plasma 
membranes or from endosomes and other subcellular organelles.  
Sphingolipids, as a subset of cellular membrane components, have been 
shown to influence lipid raft formation and have been proposed to play a role 
in cell signaling, trafficking, sorting, polarization and apoptosis. We found 
that 10% of all lipids of HIEs were comprised of sphingolipids (Paper II). 
The most dominant sphingolipids were sphingomyelin, ceramide, sulfatide 
and non-acidic glycosphingolipids. Galactosylceramides (GalCers) made up 
about 0.2% of all the lipids, but the amount of complex glycosphingolipids in 
HIEs was not assessed. Considering the lipid distribution within biological 
membranes, it is important to understand that lipids, based on their chemical 
properties and enzymatic transporters, are distributed heterogeneously. If we 
estimate that the majority of glycosphingolipids are concentrated in the outer 
layer of the apical surface of the plasma membrane, this should lead to a high 
density of glycosphingolipids there compared to other lipid classes, which 
emphasizes the risk of underrating the importance to study 
glycosphingolipids. Based on TLC technique we could identify HBGA 
epitopes on sphingolipids of cells, which comprise amounts similar to that of 
GalCers. Importantly, we could pinpoint major ABH and Lewis antigens 
present on sphingolipids using monoclonal antibody overlays. The 
distribution of these antigens among different HIEs correlated to the known 
ABO, Lewis and secretor geno- and phenotype of the cell cultures. We could 
not detect HBGA epitopes on type 2 chains GSLs, but they were all 
dominated by type 1 chain (lactoseries) structures nor could we detect any 
sialic acids in the lipid extracts from HIEs. Recent studies have shown that 
the replication of HuNoV GII.4 strains in HIEs is dependent on the secretor 
gene. In fact, secretor negative HIEs are resistant to the GII.4 infection, while 
overexpression of FUT2 gene in such cells leads to a secretor positive 
phenotype and allows for infection. Indeed, secretor-dependent GII.4 
replication is not an unexpected finding, based on earlier literature data, but 
the lipid characterization of HIEs provides background data for a new 
experimental setting to further study different steps of this infection. Our 
TIRF microscopy binding experiments could, for the first time, assay lipid 
extracts from different HIEs as to their binding of HuNoV VLPs. Our data 
confirm that GII.4 VLPs, similar to the GII.4 virus in inocula, preferentially 
bind to secretor gene dependent structures in HIE lipid extracts containing 
HBGA epitopes on glycosphingolipids. This finding supports 
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glycosphingolipids to be one of the important attachment factors for human 
norovirus.   
Our glycoproteomics approach to characterize glycoproteins from HIEs is the 
first global characterization of such cell cultures (Paper III). There was only 
one attempt to describe glycoproteins from human intestine before referring 
to findings from two individuals (478). Paper III represents findings from 
enteroids derived from stem cells from the small intestine of six individuals, 
and emphasizes the feasibility of the HIE experimental setting. Moreover, it 
allows us not only to look into the content of membrane proteins, but also to 
compare findings among different HIEs, thus among different individuals. 
We describe the diversity and complexity of tryptic glycopeptides not only 
from one protein, but from more than 100 glycoproteins. The majority of 
glycoproteins analyzed contained high-mannose N-linked glycans, while 
others were of the hybrid or complex types. Some identified glycosites 
contained only high-mannose glycoforms or only complex type glycans 
whereas others contained high-mannose, hybrid and complex types reflecting 
the glycosylation process from early synthesis in the ER to Golgi and final 
presentation on the plasma membrane. Though we looked into membrane 
proteins from HIEs, the employed extraction method does not allow the 
separation of plasma membrane from cellular organelles. Nevertheless, 
conclusions from the 40 most common glycoproteins among all 7 tested HIEs 
narrows the candidate list down to a possible viral receptor of proteinaceous 
nature for HuNoV. In fact, defining and comparing HBGA epitopes from just 
a few selected glycoproteins of 4 individual HIEs, suggested essentially the 
same glycan patterns irrespectively of the glycoprotein analyzed. Most 
importantly, this study found a strong correlation of HBGA epitopes on 
glycoproteins to the known geno- and phenotype of the cells, and has given 
support for a dependence of HBGA epitopes on glycoproteins for effective 
GII.4 HuNoV infection.  Though it is difficult to resolve the chain type of 
HBGA epitopes using MS analyses, we argue that the glycans studied were 
dominated by, but not exclusively, the type 1 chain due to the correlation to 
an active secretor gene (FUT2) expression in human intestine. Finally, the 
results from both Paper II and Paper III are in agreement with each other’s 
detailed characterization of glycosphingolipid and glycoprotein HBGA 
epitopes. Future studies should resolve if any of the described HBGA epitope 
carriers serve as a functional receptor to facilitate adhesion to target cells for 
HuNoV.   
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6.3 PAPER IV. TOWARDS A NOVEL MUCOSAL 
SUBCOMPONENT VACCINE AGAINST 
HUMAN NOROVIRUS INFECTION 
We do not have a vaccine against HuNoV, but clinical trials are ongoing. 
However, the development of a vaccine against norovirus has been facing 
several challenges over the years. More specifically, the lack of experimental 
models has slowed the progress in vaccine development and left complete 
reliance on testing in clinical trials. Hence, the outcome of clinical testing is 
not preceded by pre-clinical testing of the vaccine and, thus, little information 
exists as to what to expect from a fully protective NoV vaccine. Therefore, 
the unavailability of a good animal model or the lack of a cell culturing 
system has greatly hampered vaccine development. A majority of 
experimental studies has been relying on VLPs or P particles as vaccine 
components, which are thought to retain most of the immunogenicity of the 
whole virus. Human challenge studies using different genogroups of the 
human virus have revealed the lack of cross-reactive antibodies against virus 
strains. Indeed, it is thought that antigenic drift among new strains of HuNoV 
is one of the important reasons for the lack of protection against the virus in 
humans. Furthermore, neither challenge studies nor the ongoing clinical 
phase trials of vaccine candidates could find immune responses lasting for 
more than 2 years or more than 12 months, respectively. Clearly, it appears 
that the VLP-vaccine poorly stimulates immunological memory, which is 
required from an effective NoV vaccine. Therefore, in Paper IV we have 
explored a novel strategy for generating a mucosal subcomponent vaccine 
and have designed the vaccine based on an adjuvant active fusion protein, 
CTA1-DD. 
We developed MAbs against GII.4 norovirus VLP and tested their reactivities 
towards peptides, derived from the same VLP using a peptide array with 
overlapping 15-mers. One of the tested MAbs demonstrated reactivity to 
several fragments from the capsid, as well as cross-reactivity against 
antigenically distant norovirus VLPs. Furthermore, selected peptides were 
exposed on the capsid suggesting a good proximity to the MAb binding site. 
In addition, these peptides contained preserved amino acid sequences shared 
by a high proportion of norovirus strains. Interestingly, using in silico affinity 
prediction method, we could identify that one of the selected peptides was 
also found to host a high affinity to MHC class II molecules. Another CD4 T 
cell restricted peptide was identified after screening all the peptides from the 
same capsid by consulting the in silico algorithms. Furthermore, these MHC 
class II restricted peptides were predicted to be of high affinity in both mice 
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and humans. Finally, we could confirm the superior immunogenicity of 
soluble peptides in the mouse model, which supports the in silico predictions 
and the validity for our choice of strategy.   
Next step was to generate different fusion proteins to test whether a peptide-
specific response could be stimulated. The 5 peptides were inserted into the 
fusion protein, CTA1-DD, which has self-adjuvanting properties. To our 
surprise, none of the immunizations with the designed fusion proteins could 
stimulate an immune response, albeit the peptides had earlier proven to 
stimulate acceptable responses when given combined with an adjuvant. 
Because of this result we speculated that maybe it was possible that the 
critical epitopes were degraded and could not be presented by DCs. We 
investigated whether cathepsin D, could digest the fusion proteins into 
fragments that had lost their immunogenicity. The most abundant protease, 
found in endosomes of antigen presenting cells, hydrolyzed our fusion 
proteins in vitro, including the inserted peptides, into non-immunogenic 
fragments.  This outcome indicated that the peptides were susceptible to 
cathepsin D cleavage and could possibly be exposed and hydrolyzed by the 
protease also in vivo. Therefore, we have considered redesigning of our 
fusion proteins to better resist degradation.  
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7 FUTURE PERSPECTIVES 
Glycosphingolipids and glycoproteins from HIEs 
HIEs open up tremendous new opportunities to investigate the complexity of 
glycosylation in individual intestinal epithelia at the molecular and 
transcriptional levels. It is now possible to analyze binding kinetics of 
vesicles prepared from lipid extracts of target cells to VLPs of different 
strains using TIRFM technology. Furthermore, single binding 
glycosphingolipid components can be examined with specific addition of 
cholesterol or sphingomyelin on a relevant glycerophospholipid background. 
Since VLPs can also be labeled, it will be of interest to trace binding 
dynamics on the surface prepared from lipid extracts of HIEs. Just by 
studying HIEs from six individuals led us into unexpected genotype vs. 
phenotype results expressed on glycosphingolipids in a single individual. 
This particular HIE line (J10) has been genotyped as secretor negative 
(FUT2-/-), Lewis negative (FUT3-/-) and A positive (AO), but the lipid 
extracts from J10 were repeatedly reactive to an anti-A antibody, indicating 
the presence of small amounts of an A-like antigen on glycosphingolipids. 
This unexpected and divergent finding will be addressed in greater detail in 
future studies, in which we will also investigate the presence of HBGA 
structures of different types on glycosphingolipids and glycoproteins. We 
will also include an extended glycome analysis of 
glycosphingolipids/glycoproteins in J10 cells, including genetically 
engineered J10 clones with overexpression of FUT2 and FUT3 genes. The 
role of glycoproteins in HuNoV infection of HIEs will require additional data 
from the infection model. This is possible to address through engineered 
HIEs losing their susceptibility to the infection, or other cell lines gaining 
sensitivity to the infection. These studies should then be complemented by 
enrichment and LC-MS/MS analysis of specific glycoproteins from 
susceptible HIE lines. In this way, HIE studies will identify receptors and 
attachment factors essential for HuNoV infection caused by specific virus 
strains/genotypes/genogroups. Indeed, HIEs allow studies of single 
individuals in a simplified experimental model, where numerous questions 
can be applied to study the physiology and pathology of intestinal cells from 
different segments of the gut. HIEs will allow the setup of different infectious 
and cancer models, therapeutic interventions, and even co-cultures with 
additional types of cells forming small functional organisms ex vivo in a 
single well. Certainly, extended panels of individual HIEs will open doors 
into precision medicine of advanced prevention and treatment strategies in 
humans, including strategies against HuNoV infections.  
Inga Rimkutė 
 
75 
Redesign of fusion proteins 
To optimize the design of our vaccine, we will improve the presentation of 
immunogenic peptides in the fusion protein. After identifying linear CD4 T-
cell specific peptides, we now know these could be completely degraded by 
intracellular processing.   The studies with cathepsin D have clearly identified 
that we can engineer the fusion protein to host less susceptible peptides for 
protease degradation. This could be improved by modifying the sensitive 
regions of the fusion protein to achieve a better protected set of peptides less 
easily digested by the antigen processing cell. This will, hopefully, preserve 
their immunogenicity. Using our strategy to identify immunogenic peptides it 
is also possible to identify peptides that are less sensitive to proteases. 
Subsequently, insertion of selected peptides into the CTA1-DD adjuvant 
platform adding novel cleavage sites to attract proteases away from the 
peptides could be a way forward. Similarly, the B cell epitopes would require 
a better presentation so that they are more effective in cross-binding the B 
cell receptor so that B cells become activated. We identified several peptides 
reactive with our MAb, including possible linear B cell epitopes. Presentation 
of these linear epitopes in the fusion protein construct failed due to the 
digestion by cathepsin D. An alternative method is to replace sensitive 
regions of the fusion protein by substitution of amino acids in the fusion 
protein. Indeed, the linear epitope may transform and undergo conformational 
changes when inserted into the fusion protein. Therefore, another strategy is 
to employ tagging of the peptides to scaffolds, which might be a better 
approach to preserve the presentation of linear B cell epitopes.  Nevertheless, 
we will challenge the classical VLP-based vaccine approach and develop a 
mucosal subcomponent vaccine against HuNoV. We will use carefully 
selected peptides and the adjuvant CTA1-DD formulation in further refining 
the vaccine candidate. Future pre-clinical studies of vaccine candidates 
against norovirus would benefit from an engineered animal model expressing 
receptors and attachment factors allowing the HuNoV infection in vivo.  
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